#sarbecovirus — Public Fediverse posts

Re-infection with #SARS-CoV-2 is associated with increased #antibody breadth and potency against diverse #sarbecovirus strains, https://etidiohnew.blogspot.com/2026/02/re-infection-with-sars-cov-2-is.html

#Bat #sarbecovirus WIV1-CoV bears an adaptive #mutation that alters #spike dynamics and enhances #ACE2 binding, https://etidiohnew.blogspot.com/2025/10/bat-sarbecovirus-wiv1-cov-bears.html

#Bat #sarbecovirus WIV1-CoV bears an adaptive #mutation that alters #spike dynamics and enhances #ACE2 binding, https://etidiohnew.blogspot.com/2025/10/bat-sarbecovirus-wiv1-cov-bears.html

#Bat #sarbecovirus WIV1-CoV bears an adaptive #mutation that alters #spike dynamics and enhances #ACE2 binding, https://etidiohnew.blogspot.com/2025/10/bat-sarbecovirus-wiv1-cov-bears.html

#Bat #sarbecovirus WIV1-CoV bears an adaptive #mutation that alters #spike dynamics and enhances #ACE2 binding, https://etidiohnew.blogspot.com/2025/10/bat-sarbecovirus-wiv1-cov-bears.html

#Bat #sarbecovirus WIV1-CoV bears an adaptive #mutation that alters #spike dynamics and enhances #ACE2 binding, https://etidiohnew.blogspot.com/2025/10/bat-sarbecovirus-wiv1-cov-bears.html

Broadly #Sarbecovirus-Neutralizing #Antibodies Induced by Ancestral #SARS-CoV-2 #Infection, https://etidiohnew.blogspot.com/2025/09/broadly-sarbecovirus-neutralizing.html

#Bat #sarbecovirus WIV1-CoV bears an adaptive #mutation that alters spike dynamics and enhances #ACE2 binding, https://etidiohnew.blogspot.com/2025/04/bat-sarbecovirus-wiv1-cov-bears.html

#Bat #sarbecovirus WIV1-CoV bears an adaptive #mutation that alters spike dynamics and enhances #ACE2 binding, https://etidiohnew.blogspot.com/2025/04/bat-sarbecovirus-wiv1-cov-bears.html

#Bat #sarbecovirus WIV1-CoV bears an adaptive #mutation that alters spike dynamics and enhances #ACE2 binding, https://etidiohnew.blogspot.com/2025/04/bat-sarbecovirus-wiv1-cov-bears.html

#Bat #sarbecovirus WIV1-CoV bears an adaptive #mutation that alters spike dynamics and enhances #ACE2 binding, https://etidiohnew.blogspot.com/2025/04/bat-sarbecovirus-wiv1-cov-bears.html

#Bat #sarbecovirus WIV1-CoV bears an adaptive #mutation that alters spike dynamics and enhances #ACE2 binding, https://etidiohnew.blogspot.com/2025/04/bat-sarbecovirus-wiv1-cov-bears.html

A trivalent #mucosal #vaccine encoding phylogenetically inferred ancestral #RBD #sequences confers pan- #Sarbecovirus #protection in mice https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(24)00403-7?rss=yes

Case et al. use ancestral phylogenetic reconstructions of Sarbecovirus sequences to generate a pan-Sarbecovirus vaccine. In mice, vaccine confers protection vs all tested Sarbecoviruses, including #SARS-CoV, multiple SARS-CoV-2 #variants, & pre-emergent Sarbecovirus strains.

#Coronavirus Disease Research #References (by AMEDEO, December 7 ’24)

1. VASSILOPOULOS S, Mylonakis E
   After COVID-19 diagnosis, risk for incident type 2 diabetes was elevated for up to 2 y.
   Ann Intern Med. 2024 Dec 3. doi: 10.7326/ANNALS-24-02887.
   PubMed         Abstract available

   Antiviral Res

2. SCHRELL L, Fuchs HL, Dickmanns A, Scheibner D, et al
   Inhibitors of dihydroorotate dehydrogenase synergize with the broad antiviral activity of 4′-fluorouridine.
   Antiviral Res. 2024 Dec 3:106046. doi: 10.1016/j.antiviral.2024.106046.
   PubMed         Abstract available

   Br J Anaesth

3. SPARLING JL, Chitilian HV, Korn E, Alfille PH, et al
   Induction of anaesthesia and airway management in patients with severe tracheal stenosis: a single-centre retrospective study.
   Br J Anaesth. 2024 Dec 4:S0007-0912(24)00667-6. doi: 10.1016/j.bja.2024.
   PubMed        

   Emerg Infect Dis

4. HASSAN AM, Muhlemann B, Al-Subhi TL, Rodon J, et al
   Ongoing Evolution of Middle East Respiratory Syndrome Coronavirus, Saudi Arabia, 2023-2024.
   Emerg Infect Dis. 2024;31.
   PubMed         Abstract available

   Infect Control Hosp Epidemiol

5. KIM T, Moehring RW, Turner NA, Ashley ED, et al
   Long-term trends in the incidence of hospital-acquired carbapenem-resistant Enterobacterales and antimicrobial utilization in a network of community hospitals in the Southeastern United States from 2013 to 2023.
   Infect Control Hosp Epidemiol. 2024 Dec 3:1-7. doi: 10.1017/ice.2024.
   PubMed         Abstract available
6. USIAK S, Aslam A, Yan J, Madhavappallil J, et al
   Utility of post-admission SARS-CoV-2 serial testing in hospitalized patients with cancer.
   Infect Control Hosp Epidemiol. 2024 Dec 3:1-3. doi: 10.1017/ice.2024.
   PubMed         Abstract available
7. PASSARETTI CL, Bischoff W, Chan J, Diekema DJ, et al
   Respiratory equality: let’s stop playing favorites with COVID-19 in the healthcare setting.
   Infect Control Hosp Epidemiol. 2024 Dec 4:1-2. doi: 10.1017/ice.2024.
   PubMed        

   Int J Infect Dis

8. IP B, Pan S, Yao A, Lau L, et al
   COVID-19 vaccination and cerebral small vessel disease progression – A prospective cohort study.
   Int J Infect Dis. 2024 Dec 3:107324. doi: 10.1016/j.ijid.2024.107324.
   PubMed         Abstract available

   J Infect

9. PENG Y, Shen H, Zhang Y, Zeng S, et al
   A comprehensive pan-cancer analysis of SARS-CoV-2-related cancer malignancy: COVID-19 infection shapes a dynamic immune microenvironment and affects the prognosis.
   J Infect. 2024 Nov 30:106364. doi: 10.1016/j.jinf.2024.106364.
   PubMed        

   J Med Virol

10. ZWYGART AC, Medaglia C, Zhu Y, Bart Tarbet E, et al
    Development of Broad-Spectrum beta-Cyclodextrins-Based Nanomaterials Against Influenza Viruses.
    J Med Virol. 2024;96:e70101.
    PubMed         Abstract available
11. STICH M, Magalhaes VG, Burger F, Garbade SF, et al
    Elevated Soluble ACE2 Activity in Children and Adults After SARS-CoV-2 Exposure Irrespective of Laboratory-Confirmed Infection.
    J Med Virol. 2024;96:e70098.
    PubMed         Abstract available
12. MAIMAITI M, Kong L, Yu Q, Wang Z, et al
    Analytical Performance of a Novel Nanopore Sequencing for SARS-CoV-2 Genomic Surveillance.
    J Med Virol. 2024;96:e70108.
    PubMed         Abstract available

    J Virol

13. ZUO F, Cao Y, Sun R, Wang Q, et al
    Ultrapotent IgA dimeric antibodies neutralize emerging Omicron variants.
    J Virol. 2024 Dec 4:e0174024. doi: 10.1128/jvi.01740.
    PubMed        
14. ZHANG Y, Zhang N, Zhang Y, Li Y, et al
    Potassium molybdate blocks APN-dependent coronavirus entry by degrading receptor via PIK3C3-mediated autophagy.
    J Virol. 2024 Dec 6:e0144924. doi: 10.1128/jvi.01449.
    PubMed         Abstract available

    JAMA

15. ANDERER S
    CDC Recommends Second COVID-19 Vaccine Dose for Older Adults.
    JAMA. 2024 Dec 6. doi: 10.1001/jama.2024.24258.
    PubMed        

    Nature

16. KUDIABOR H
    Virtual lab powered by ‘AI scientists’ super-charges biomedical research.
    Nature. 2024 Dec 4. doi: 10.1038/d41586-024-01684.
    PubMed        

    Science

17. KAISER J
    Trump picks an ‘outsider’ and NIH critic to lead agency.
    Science. 2024;386:1080-1081.
    PubMed         Abstract available

#betacoronavirus #covid #COVID19 #health #mentalHealth #research #sarbecovirus #sarsCov2 #science

#Coronavirus Disease Research #References (by AMEDEO, December 1 ’24)

1. MCGOVERN-GOOCH KR, Mani N, Gotchev D, Ardzinski A, et al
   Biological characterization of AB-343, a novel and potent SARS-CoV-2 M(pro) inhibitor with pan-coronavirus activity.
   Antiviral Res. 2024;232:106038.
   PubMed         Abstract available
2. AMIN MR, Anwar KN, Ashraf MJ, Ghassemi M, et al
   Preventing human influenza and coronaviral mono or coinfection by blocking virus-induced sialylation.
   Antiviral Res. 2024;232:106041.
   PubMed         Abstract available
3. GENG X, Zhu Y, Gao Y, Chong H, et al
   Development of lipopeptide-based HIV-1/2 fusion inhibitors targeting the gp41 pocket site with a new design strategy.
   Antiviral Res. 2024 Nov 23:106042. doi: 10.1016/j.antiviral.2024.106042.
   PubMed         Abstract available

   BMJ

4. ZERAATKAR D, Ling M, Kirsh S, Jassal T, et al
   Interventions for the management of long covid (post-covid condition): living systematic review.
   BMJ. 2024;387:e081318.
   PubMed         Abstract available

   Clin Infect Dis

5. TOWNSEND JP, Hassler HB, Dornburg A
   Optimal Annual COVID-19 Vaccine Boosting Dates Following Previous Booster Vaccination or Breakthrough Infection.
   Clin Infect Dis. 2024 Nov 26:ciae559. doi: 10.1093.
   PubMed         Abstract available
6. FAUCI AS, Folkers GK
   HIV/AIDS and COVID-19: Shared Lessons from Two Pandemics.
   Clin Infect Dis. 2024 Nov 27:ciae585. doi: 10.1093.
   PubMed         Abstract available
7. LEWIS NM, Harker EJ, Grant LB, Zhu Y, et al
   Benefit of early oseltamivir therapy for adults hospitalized with influenza A: an observational study.
   Clin Infect Dis. 2024 Nov 28:ciae584. doi: 10.1093.
   PubMed         Abstract available

   Infect Control Hosp Epidemiol

8. SANDS KE, Blanchard EJ, Hasse A, Korwek K, et al
   Risk factors for healthcare-associated infection among patients hospitalized with COVID-19 infection.
   Infect Control Hosp Epidemiol. 2024 Nov 25:1-2. doi: 10.1017/ice.2024.
   PubMed        

   Int J Infect Dis

9. CHUN HM, Osawe S, Adams-Dabban S, Favaloro J, et al
   SARS-CoV-2 Serologic Surveillance Among People Living with HIV in Nigeria, April 2022-January 2023.
   Int J Infect Dis. 2024 Nov 21:107309. doi: 10.1016/j.ijid.2024.107309.
   PubMed         Abstract available
10. YANG X, Zhang J, Liu Z, Chen S, et al
    Real-world effectiveness of COVID-19 vaccine in people with HIV compared with a matched HIV-negative cohort: a test-negative design.
    Int J Infect Dis. 2024 Nov 22:107310. doi: 10.1016/j.ijid.2024.107310.
    PubMed         Abstract available
11. PETT SL
    Predictors of hospitalisation, death and incomplete/non-recovery from SARS-CoV-2 in an ambulatory global population.
    Int J Infect Dis. 2024 Nov 26:107285. doi: 10.1016/j.ijid.2024.107285.
    PubMed         Abstract available

    J Infect

12. JIA T, Wang F, Chen Y, Liao G, et al
    Expanded immune imprinting and neutralization spectrum by hybrid immunization following breakthrough infections with SARS-CoV-2 variants after three-dose vaccination.
    J Infect. 2024 Nov 26:106362. doi: 10.1016/j.jinf.2024.106362.
    PubMed         Abstract available

    J Med Virol

13. SIDDIQUE AI, Sarmah N, Bali NK, Nausch N, et al
    Differential Gene Expression and Transcriptomics Reveal High M-Gene Expression in JN.1 and KP.1/2 Omicron Sub-Variants of SARS-CoV-2: Implications for Developing More Sensitive Diagnostic Tests.
    J Med Virol. 2024;96:e70074.
    PubMed         Abstract available
14. USHIJIMA H, Pham NTK, Nishimura S, Kobayashi M, et al
    Human Astrovirus Infection and Outbreaks in Japanese Children Before and After the Emergence of COVID-19 Pandemic.
    J Med Virol. 2024;96:e70078.
    PubMed         Abstract available
15. CHEN J, Zhang Y, Zhang B, Wang Z, et al
    In Vitro Characterization of Inhibition Function of Calcifediol to the Protease Activity of SARS-COV-2 PLpro.
    J Med Virol. 2024;96:e70085.
    PubMed         Abstract available
16. TIAN W, Han Z, Shi D, Wang H, et al
    Indeterminate Result of Interferon-gamma Release Assay-A Risk Factor of Mortality for COVID-19 and Non-COVID-19 Respiratory Infections.
    J Med Virol. 2024;96:e70058.
    PubMed         Abstract available
17. GRANINGER M, Endmayr V, Kuhner LM, Berger SM, et al
    Association Between NK Cell Genetic Variants and the Development of Long COVID Associated- and Prepandemic Small Fiber Neuropathy.
    J Med Virol. 2024;96:e70091.
    PubMed         Abstract available
18. WANG J, Ni S, Chen Q, Wang C, et al
    Discovery of a Novel Public Antibody Lineage Correlated With Inactivated SARS-CoV-2 Vaccine and the Resultant Neutralization Activity.
    J Med Virol. 2024;96:e70073.
    PubMed         Abstract available

    J Virol

19. KAKIZAKI M, Hashimoto R, Nagata N, Yamamoto T, et al
    The respective roles of TMPRSS2 and cathepsins for SARS-CoV-2 infection in human respiratory organoids.
    J Virol. 2024 Nov 27:e0185324. doi: 10.1128/jvi.01853.
    PubMed         Abstract available

    Lancet

20. FERRANTE M, D’Haens G, Jairath V, Danese S, et al
    Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn’s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
    Lancet. 2024 Nov 21:S0140-6736(24)01762-8. doi: 10.1016/S0140-6736(24)01762.
    PubMed         Abstract available
21. DWYER-LINDGREN L, Baumann MM, Li Z, Kelly YO, et al
    Ten Americas: a systematic analysis of life expectancy disparities in the USA.
    Lancet. 2024 Nov 19:S0140-6736(24)01495-8. doi: 10.1016/S0140-6736(24)01495.
    PubMed         Abstract available

    Lancet Infect Dis

22. GOSWAMI J, Cardona JF, Hsu DC, Simorellis AK, et al
    Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial.
    Lancet Infect Dis. 2024 Nov 25:S1473-3099(24)00589.
    PubMed         Abstract available
23. LIU J, Yu Y, Jian F, Yang S, et al
    Enhanced immune evasion of SARS-CoV-2 variants KP.3.1.1 and XEC through N-terminal domain mutations.
    Lancet Infect Dis. 2024 Nov 22:S1473-3099(24)00738.
    PubMed        

    Science

24. LIBBY P
    Endothelial inflammation in COVID-19.
    Science. 2024;386:972-973.
    PubMed         Abstract available
25. COHEN J
    Children are left behind in Congo’s mpox vaccination drive.
    Science. 2024;386:954.
    PubMed         Abstract available

    Travel Med Infect Dis

26. KHAN AA, Balkhi BS, Alamri FA, Alsaleh GS, et al
    Vaccinations for Hajj: Enhancing health and global health security.
    Travel Med Infect Dis. 2024;63:102784.
    PubMed         Abstract available
27. WANG J, Ge L, Zhou K, Jiang Y, et al
    Effect of omicron infection on maternal and neonatal delivery outcomes: A retrospective cohort study.
    Travel Med Infect Dis. 2024;62:102759.
    PubMed         Abstract available

#abstract #betacoronavirus #covid #COVID19 #health #research #sarbecovirus #sarsCov2 #vaccine

#Recombination across distant #coronavirid #species and #genera is a rare #event with distinct #genomic features

Source: Journal of Virology, https://journals.asm.org/doi/full/10.1128/jvi.01100-24?af=R

ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; family Coronaviridae, genus Betacoronavirus, subgenus Sarbecovirus) has caused millions of deaths, prompting a need for better understanding of coronavirid emergence and spillover to humans. As an evaluation of how some features of SARS-CoV-2, unique among sarbecoviruses, may have been acquired from related viruses, we conducted phylogenetic and recombination analyses to compare the frequency of recombination among coronavirids across vs within genera, subgenera, and species. Among known betacoronaviruses, we identified 199 (183 intraspecies, 16 interspecies, but no intersubgenera) recombination events. Phylogenetic analyses revealed that the ancestry of interspecies events was limited and less prone to affect 5′ regions of coronavirid genome open reading frame 1 (ORF1) than intraspecies events. On the contrary, interspecies events were significantly more prone to impact the 3′ end (ORF6–ORF8 and the nucleocapsid protein [N] ORF), suggesting the existence of region-specific constraints on recombination. This work substantiated that recombination among betacoronaviruses is limited by the genome similarity between their parental viruses. We conclude that SARS-CoV-2 likely acquired unique features through recombination with closely related circulating sarbecoviruses (most likely from the same species) that co-existed geographically.

____

#abstract #betacoronavirus #biology #coronavirus #evolution #genetics #health #research #sarbecovirus #sarsCov2 #science

#Coronavirus Disease Research #References (by AMEDEO, Nov. 16 ’24)

1. AYYALA-SOMAYAJULA D, Dodge JL, Leventhal AM, Terrault NA, et al
   Trends in Alcohol Use After the COVID-19 Pandemic: A National Cross-Sectional Study.
   Ann Intern Med. 2024 Nov 12. doi: 10.7326/ANNALS-24-02157.
   PubMed        

   Antiviral Res

2. SAMA B, Selisko B, Falcou C, Fattorini V, et al
   The effects of Remdesivir’s functional groups on its antiviral potency and resistance against the SARS-CoV-2 polymerase.
   Antiviral Res. 2024 Nov 5:106034. doi: 10.1016/j.antiviral.2024.106034.
   PubMed         Abstract available

   BMJ

3. GREENHALGH T, Misak C, Payne R, Swann N, et al
   Patient involvement in developing clinical guidelines.
   BMJ. 2024;387:q2433.
   PubMed        

   Br J Anaesth

4. ANGELOPOULOS N, Staines J, Chamberlin M, Bates S, et al
   A narrative review of personal protective equipment gowns: lessons from COVID-19.
   Br J Anaesth. 2024 Nov 7:S0007-0912(24)00567-1. doi: 10.1016/j.bja.2024.
   PubMed         Abstract available

   Clin Infect Dis

5. GRANT R, de Kraker MEA, Buetti N, Jackson H, et al
   In-hospital outcomes of healthcare-associated COVID-19 (Omicron) versus healthcare-associated influenza: a retrospective, nationwide cohort study in Switzerland.
   Clin Infect Dis. 2024 Nov 13:ciae558. doi: 10.1093.
   PubMed         Abstract available
6. HAMMOND J, Leister-Tebbe H, Gardner A, Abreu P, et al
   Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-Risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A phase 3 randomized trial.
   Clin Infect Dis. 2024 Nov 11:ciae551. doi: 10.1093.
   PubMed         Abstract available

   Emerg Infect Dis

7. CREPPAGE KE, Gallaway MS, Russell DA, Early JM, et al
   Global Emerging Infections Surveillance Program Contributions to Pandemic Preparedness and Response.
   Emerg Infect Dis. 2024;30:9-12.
   PubMed         Abstract available
8. MORTON LC, Rahman N, Bishop-Lilly KA
   Next-Generation Sequencing and Bioinformatics Consortium Approach to Genomic Surveillance.
   Emerg Infect Dis. 2024;30:13-18.
   PubMed         Abstract available
9. MUEHLEMAN D, Gruner B, Hogan V, Fanning P, et al
   Using SARS-CoV-2 Sequencing Data to Identify Reinfection Cases in the Global Emerging Infections Surveillance Program, United States.
   Emerg Infect Dis. 2024;30:53-61.
   PubMed         Abstract available
10. TINOCO YO, Osman TS, Ampuero JS, Gazo M, et al
    Respiratory Disease Surveillance in the Middle East and Latin America during the COVID-19 Pandemic, 2020-2022.
    Emerg Infect Dis. 2024;30:26-32.
    PubMed         Abstract available
11. ODUNDO EA, Kipkirui EC, Koech MC, Kirui MC, et al
    Azithromycin Resistance Patterns in Escherichia coli and Shigella before and after COVID-19, Kenya.
    Emerg Infect Dis. 2024;30:86-93.
    PubMed         Abstract available

    Int J Infect Dis

12. GRIFFITHS M, Hatabah D, Sullivan P, Mantus G, et al
    Corrigendum to “Incidence of SARS-CoV-2 seropositivity in pediatric healthcare workers prior to widespread vaccination: A 5-month longitudinal cohort study” [Internation Journal of Infectious Diseases, volume 144 (2024) 107064].
    Int J Infect Dis. 2024;149:107278.
    PubMed        
13. LASTRUCCI V, Pacifici M, Puglia M, Alderotti G, et al
    Erratum to ‘Seasonality and severity of respiratory syncytial virus during the COVID-19 pandemic: a dynamic cohort study’.
    Int J Infect Dis. 2024;149:107286.
    PubMed        

    Intensive Care Med

14. KESECIOGLU J, Rusinova K, Alampi D, Arabi YM, et al
    European Society of Intensive Care Medicine guidelines on end of life and palliative care in the intensive care unit.
    Intensive Care Med. 2024 Oct 3. doi: 10.1007/s00134-024-07579.
    PubMed         Abstract available
15. OLMOS M, Esperatti M, Fuentes N, Miranda Tirado A, et al
    Early physiologic changes after awake prone positioning predict clinical outcomes in patients with acute hypoxemic respiratory failure.
    Intensive Care Med. 2024 Nov 14. doi: 10.1007/s00134-024-07690.
    PubMed         Abstract available

    J Infect

16. DULFER EA, Fohse K, Taks EJM, Moorlag SJCFM, et al
    The effect of BCG vaccination in the elderly on infectious and non-infectious immune-mediated diseases.
    J Infect. 2024;89:106344.
    PubMed         Abstract available
17. HAN B, Du C, Deng M, Tang R, et al
    Real-world effectiveness and safety of simnotrelvir/ritonavir for COVID-19: A nationwide, multicenter, prospective, observational cohort study in China.
    J Infect. 2024 Nov 7:106339. doi: 10.1016/j.jinf.2024.106339.
    PubMed         Abstract available
18. FOONG KS
    Corrigendum to “The IL-6 hypothesis in COVID-19: A phase 2, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of free IL-6 sequestration by the monoclonal antibody sirukumab in severe and critical COVID-19” [J Infe
    J Infect. 2024;89:106343.
    PubMed        

    J Med Virol

19. USTIUZHANINA MO, Boyko AA, Vavilova JD, Siniavin AE, et al
    The Antigen-Specific Response of NK Cells to SARS-CoV-2 Correlates With KIR2DS4 Expression.
    J Med Virol. 2024;96:e70057.
    PubMed         Abstract available
20. ZHANG C, Wang M, Sun S, Yi M, et al
    Impact of COVID-19 on the Prevalence and Drug Resistance of Bacteria Isolated From Bacterial Meningitis Cerebrospinal Fluid in Shandong Province: A Multicenter Retrospective Study.
    J Med Virol. 2024;96:e70063.
    PubMed         Abstract available
21. ESPI M, Charmetant X, Benotmane I, Lefsihane K, et al
    Memory B Cells Provide Long-Term Protection to Vaccinated Kidney Transplant Recipients Against SARS-CoV-2 Variants.
    J Med Virol. 2024;96:e70037.
    PubMed         Abstract available
22. FACCO JV, Addas-Carvalho M, Duarte ADSS, Zangirolami AB, et al
    HLA-B*15 Is Associated With SARS-CoV-2 Infection in a Brazilian Population.
    J Med Virol. 2024;96:e70028.
    PubMed         Abstract available
23. WANG N, Lin Q, Fan H, Wang Y, et al
    BIC/FTC/TAF Benefits People Living With HIV After Omicron Breakthrough Infection in Shortening Duration of Symptoms, Enhancing Specific Immune Response and Increasing Total CD4 Cells.
    J Med Virol. 2024;96:e70036.
    PubMed         Abstract available
24. YE C, Tian Y, Huo D, Zhang T, et al
    Changes in Epidemics of Respiratory Viral Infections Resulted From the COVID-19 Pandemic in Shanghai.
    J Med Virol. 2024;96:e70034.
    PubMed         Abstract available

    J Virol

25. CHEN Y, Ou X, Li P, Zan F, et al
    Identification of the critical residues of TMPRSS2 for entry and host range of human coronavirus HKU1.
    J Virol. 2024 Nov 11:e0158724. doi: 10.1128/jvi.01587.
    PubMed         Abstract available
26. STEIGMANN JC, Zhou X, Suttenberg LN, Salman I, et al
    Effects of immunoproteasome inhibition on acute respiratory infection with murine hepatitis virus strain 1.
    J Virol. 2024 Nov 7:e0123824. doi: 10.1128/jvi.01238.
    PubMed         Abstract available

    JAMA

27. ANDERER S
    FDA Authorizes First At-Home COVID-19 and Flu Combo Test.
    JAMA. 2024 Nov 8. doi: 10.1001/jama.2024.22561.
    PubMed        

    Lancet

28. DWYER-LINDGREN L, Kendrick P, Baumann MM, Li Z, et al
    Disparities in wellbeing in the USA by race and ethnicity, age, sex, and location, 2008-21: an analysis using the Human Development Index.
    Lancet. 2024 Nov 6:S0140-6736(24)01757-4. doi: 10.1016/S0140-6736(24)01757.
    PubMed         Abstract available
29. ALWAN NA, Al-Aly Z
    Learning from long COVID: conceptualising action to tackle infection-associated non-communicable diseases.
    Lancet. 2024 Nov 6:S0140-6736(24)02256-6. doi: 10.1016/S0140-6736(24)02256.
    PubMed        
30. Global, regional, and national stillbirths at 20 weeks’ gestation or longer in 204 countries and territories, 1990-2021: findings from the Global Burden of Disease Study 2021.
    Lancet. 2024 Nov 4:S0140-6736(24)01925-1. doi: 10.1016/S0140-6736(24)01925.
    PubMed         Abstract available

    Lancet Infect Dis

31. ARORA P, Happle C, Kempf A, Nehlmeier I, et al
    Impact of JN.1 booster vaccination on neutralisation of SARS-CoV-2 variants KP.3.1.1 and XEC.
    Lancet Infect Dis. 2024 Nov 7:S1473-3099(24)00688.
    PubMed        
32. KAKU Y, Okumura K, Kawakubo S, Uriu K, et al
    Virological characteristics of the SARS-CoV-2 XEC variant.
    Lancet Infect Dis. 2024 Nov 6:S1473-3099(24)00731.
    PubMed        

    MMWR Morb Mortal Wkly Rep

33. LEFFERTS B, Bressler S, Keck JW, Desnoyers C, et al
    Nirsevimab Effectiveness Against Medically Attended Respiratory Syncytial Virus Illness and Hospitalization Among Alaska Native Children – Yukon-Kuskokwim Delta Region, Alaska, October 2023-June 2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:1015-1021.
    PubMed         Abstract available
34. MINTA AA, Ferrari M, Antoni S, Lambert B, et al
    Progress Toward Measles Elimination – Worldwide, 2000-2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:1036-1042.
    PubMed         Abstract available

    N Engl J Med

35. SCHMIDT P, Li Y, Popejoy M
    Immunobridging for Pemivibart, a Monoclonal Antibody for Prevention of Covid-19.
    N Engl J Med. 2024;391:1860-1862.
    PubMed        
36. WANG Q, Guo Y, Ho J, Ho DD, et al
    Activity of Research-Grade Pemivibart against Recent SARS-CoV-2 JN.1 Sublineages.
    N Engl J Med. 2024;391:1863-1864.
    PubMed        
37. JASTREBOFF AM, le Roux CW, Stefanski A, Aronne LJ, et al
    Tirzepatide for Obesity Treatment and Diabetes Prevention.
    N Engl J Med. 2024 Nov 13. doi: 10.1056/NEJMoa2410819.
    PubMed         Abstract available

    Nature

38. JIAN F, Wang J, Yisimayi A, Song W, et al
    Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1.
    Nature. 2024 Nov 7. doi: 10.1038/s41586-024-08315.
    PubMed         Abstract available
39. SOLIMAN A
    US trust in scientists plunged during the pandemic – but it’s starting to recover.
    Nature. 2024 Nov 14. doi: 10.1038/d41586-024-03723.
    PubMed        

    Science

40. CHEN Z, Tsui JL, Gutierrez B, Busch Moreno S, et al
    COVID-19 pandemic interventions reshaped the global dispersal of seasonal influenza viruses.
    Science. 2024;386:eadq3003.
    PubMed         Abstract available
41. ROHANI P, Bahl J
    Collateral effects of pandemic control.
    Science. 2024;386:620-621.
    PubMed         Abstract available
42. VOGEL G
    ‘America first’ could affect health worldwide.
    Science. 2024;386:715.
    PubMed         Abstract available

#abstract #betacoronavirus #covid #COVID19 #health #news #research #sarbecovirus #sarsCov2

Source: npj Vaccines, https://www.nature.com/articles/s41541-024-01016-6

Abstract
We report SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 neutralizing antibody titers. They displayed increased immune evasion compared to JN.1, especially KP.1 and KP.3, for participants who experienced BF.7/BA.5.2 breakthrough infection or received bivalent (delta/BA.5) vaccine boosting. Second XBB sub-variants breakthrough infection enhanced the neutralization responses. HK.3-JN.1 RBD-heterodimer induced balanced and potent neutralizing responses against recently-circulating SARS-CoV-2 sub-variants in mice, supporting to replace the COVID-19 antigen containing JN.1 or its sub-variants.

_____

https://etidioh.wordpress.com/2024/11/11/neutralization-of-sars-cov-2-kp1-kp11-kp2-and-kp3-by-human-and-murine-sera/

#abstract #betacoronavirus #COVID19 #research #sarbecovirus #sarsCov2 #vaccines

1. SELINGER S
   Patients surviving COVID-19 had lower risk for long COVID in the Omicron vs. earlier eras.
   Ann Intern Med. 2024 Nov 5. doi: 10.7326/ANNALS-24-02441.
   PubMed         Abstract available

   BMJ

2. BARRETT A
   Covid-19: Australian inquiry calls for establishment of a national centre for disease control and action to tackle inequities.
   BMJ. 2024;387:q2420.
   PubMed        

   Clin Infect Dis

3. MORTEZAVI M, Sloan A, Singh RSP, Chen LF, et al
   Virologic Response and Safety of Ibuzatrelvir, a Novel SARS-CoV-2 Antiviral, in Adults With COVID-19.
   Clin Infect Dis. 2024 Nov 2:ciae529. doi: 10.1093.
   PubMed         Abstract available

   Int J Infect Dis

4. NAVEED Z, Li J, Wilton J, Naus M, et al
   Healthcare utilization among COVID-19 mRNA vaccine-associated myocarditis cases: a matched retrospective cohort study.
   Int J Infect Dis. 2024 Nov 1:107287. doi: 10.1016/j.ijid.2024.107287.
   PubMed         Abstract available
5. EPSTEIN-SHUMAN A, Hunt JH, Caturegli P, Winguth P, et al
   Autoantibodies Directed Against Interferon Alpha, Nuclear Antigens, Cardiolipin, and Beta 2 Glycoprotein 1 Are Not Induced By SARS-CoV-2 or Associated with Long COVID.
   Int J Infect Dis. 2024 Nov 1:107289. doi: 10.1016/j.ijid.2024.107289.
   PubMed         Abstract available

   Intensive Care Med

6. WANG Y, Hao S, Song J, Zhong M, et al
   Reflections on awake prone positioning in COVID-19: considerations on body inclination, respiratory support, and patient variability.
   Intensive Care Med. 2024 Nov 4. doi: 10.1007/s00134-024-07710.
   PubMed        

   J Infect

7. WANG H, Zhou Y, Chu L, Chen K, et al
   Guardian-driven influenza vaccination intentions for children post-COVID-19 in the 2024-2025 season: The positive spillover effects.
   J Infect. 2024;89:106333.
   PubMed        
8. HO A, McInnes N, Blunsum A, Quinn J, et al
   Near real-time severe acute respiratory illness surveillance characterising influenza and COVID-19 epidemiology in hospitalised adults, 2021-22.
   J Infect. 2024;89:106338.
   PubMed         Abstract available

   J Virol

9. CHEN D, Zhang W, Xiao B, Xu B, et al
   Effect of wild-type vaccine doses on BA.5 hybrid immunity, disease severity, and XBB reinfection risk.
   J Virol. 2024 Nov 5:e0128524. doi: 10.1128/jvi.01285.
   PubMed         Abstract available
10. STEIN SC, Hansen G, Ssebyatika G, Stroh LJ, et al
    A human monoclonal antibody neutralizing SARS-CoV-2 Omicron variants containing the L452R mutation.
    J Virol. 2024 Nov 4:e0122324. doi: 10.1128/jvi.01223.
    PubMed         Abstract available
11. PARRY RH, Lytras S, Petrone ME, Wille M, et al
    No evidence that mutations in SARS-CoV-2 variants of concern derive from homologous fragments in gut microbiota.
    J Virol. 2024 Nov 4:e0146824. doi: 10.1128/jvi.01468.
    PubMed         Abstract available

    Life Sci

12. MARANGI M, Boughattas S, Benslimane F
    Gut microbiome profile to the level species in diarrheic protozoan-carrier patients in Italy.
    Life Sci. 2024 Oct 25:123182. doi: 10.1016/j.lfs.2024.123182.
    PubMed         Abstract available
13. ASHRAF MS, Tuli K, Moiz S, Sharma SK, et al
    AMP kinase: A promising therapeutic drug target for post-COVID-19 complications.
    Life Sci. 2024;359:123202.
    PubMed         Abstract available

    Zhonghua Jie He He Hu Xi Za Zhi

14. LIANG SF, Li WM, Liu D
    [Progress and challenges in clinical diagnosis and treatment of co-existent lung cancer and pulmonary tuberculosis].
    Zhonghua Jie He He Hu Xi Za Zhi. 2024;47:1035-1041.
    PubMed         Abstract available

https://etidioh.wordpress.com/2024/11/10/coronavirus-disease-research-references-by-amedeo-nov-10-24/

#betacoronavirus #cancer #coronavirus #covid #COVID19 #health #mentalHealth #research #sarbecovirus #sarsCov2

1. NAKASHIMA M, Nobori H, Kuroda T, Shimba A, et al
   Oral 3CL protease inhibitor ensitrelvir suppressed SARS-CoV-2 shedding and infection in a hamster aerosol transmission model.
   Antiviral Res. 2024 Oct 28:106026. doi: 10.1016/j.antiviral.2024.106026.
   PubMed         Abstract available

   BMJ

2. DOWNAR J, Close E, Young JE, White BP, et al
   Assisted dying: balancing safety with access.
   BMJ. 2024;387:q2382.
   PubMed        

   Clin Infect Dis

3. BHIMRAJ A, Falck-Ytter Y, Kim AY, Li JZ, et al
   2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis.
   Clin Infect Dis. 2024 Oct 29:ciae435. doi: 10.1093.
   PubMed         Abstract available

   Infect Control Hosp Epidemiol

4. QADDOURA A, McQuiston M, Tyrrell G, Croxen M, et al
   Analysis of invasive group A streptococcal puerperal sepsis in Calgary, Alberta: clinical consequences and policy implications.
   Infect Control Hosp Epidemiol. 2024;45:1-4.
   PubMed         Abstract available

   J Med Virol

5. SONG K, Hasan A, Hao W, Wu Y, et al
   Stimulator of interferon genes (STING) inhibits coronavirus infection by disrupting viral replication organelles.
   J Med Virol. 2024;96:e70020.
   PubMed         Abstract available
6. YILDIZ Y, Yasar E, Ozturk E, Karakan MS, et al
   Heterologous Versus Homologous COVID-19 Boosters: Immune Response Outcomes in Renal Transplant Recipients.
   J Med Virol. 2024;96:e70030.
   PubMed         Abstract available

   J Virol

7. LIU X, Zhang M, Yin L, Kang L, et al
   PEDV evades MHC-I-related immunity through nsp1-mediated NLRC5 translation inhibition.
   J Virol. 2024 Oct 31:e0142124. doi: 10.1128/jvi.01421.
   PubMed         Abstract available
8. SHI L, Duan Y, Cao L, Zhang Y, et al
   PF-00835231 broadly inhibits swine Alpha-coronavirus, including emerging SADS-CoV.
   J Virol. 2024 Oct 31:e0130324. doi: 10.1128/jvi.01303.
   PubMed         Abstract available
9. HOFFMANN M, Kleine-Weber H, Graichen L, Nehlmeier I, et al
   Acquisition of a multibasic cleavage site does not increase MERS-CoV entry into Calu-3 human lung cells.
   J Virol. 2024 Oct 29:e0130524. doi: 10.1128/jvi.01305.
   PubMed         Abstract available

   JAMA

10. TADROUS M, Callaway Kim K, Hernandez I, Rothenberger SD, et al
    Differences in Drug Shortages in the US and Canada.
    JAMA. 2024 Oct 31. doi: 10.1001/jama.2024.17688.
    PubMed         Abstract available

    Lancet Infect Dis

11. PASCAL G
    COVID-19 in South Asia.
    Lancet Infect Dis. 2024 Oct 22:S1473-3099(24)00723.
    PubMed        
12. OKADA Y, Kumagai Y, Okura I, Otsuki M, et al
    Immunogenicity of a booster dose of a bivalent (Asp614Gly and omicron BA.4/5 variant) self-amplifying mRNA SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4/5 mRNA vaccine: a randomised phase 3 trial.
    Lancet Infect Dis. 2024 Oct 23:S1473-3099(24)00565.
    PubMed         Abstract available

    Life Sci

13. YU LC
    Gastrointestinal pathophysiology in long COVID: Exploring roles of microbiota dysbiosis and serotonin dysregulation in post-infectious bowel symptoms.
    Life Sci. 2024;358:123153.
    PubMed         Abstract available
14. WANG N, Fan H, Wang Y, Shu C, et al
    The hybrid immunity defined by weaker immune imprinting of people living with HIV has a stronger neutralizing response against Omicron variants. A suggested explanation for fewer symptoms in people living with HIV after SARS-CoV-2 variants breakthroug
    Life Sci. 2024 Oct 29:123197. doi: 10.1016/j.lfs.2024.123197.
    PubMed         Abstract available

    MMWR Morb Mortal Wkly Rep

15. BELL J, Meng L, Barbre K, Wong E, et al
    Influenza and COVID-19 Vaccination Coverage Among Health Care Personnel – National Healthcare Safety Network, United States, 2023-24 Respiratory Virus Season.
    MMWR Morb Mortal Wkly Rep. 2024;73:966-972.
    PubMed         Abstract available
16. JONES CE, Danovaro-Holliday MC, Mwinnyaa G, Gacic-Dobo M, et al
    Routine Vaccination Coverage – Worldwide, 2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:978-984.
    PubMed         Abstract available

    N Engl J Med

17. LITWINSKA-KMIECIK A, Mrowczynski K
    Postacute Sequelae of SARS-CoV-2 Infection in Several Eras.
    N Engl J Med. 2024;391:1658-1659.
    PubMed        
18. YANG C, Tebbutt SJ
    Postacute Sequelae of SARS-CoV-2 Infection in Several Eras.
    N Engl J Med. 2024;391:1659.
    PubMed        
19. XIE Y, Al-Aly Z
    Postacute Sequelae of SARS-CoV-2 Infection in Several Eras. Reply.
    N Engl J Med. 2024;391:1659-1660.
    PubMed        

    Nature

20. LIU P, Huang ML, Guo H, McCallum M, et al
    Design of customized coronavirus receptors.
    Nature. 2024 Oct 30. doi: 10.1038/s41586-024-08121.
    PubMed         Abstract available

    Science

21. LONG K
    Keeping outbreaks at bayCrisis Averted: The Hidden Science of Fighting Outbreaks Caitlin Rivers Viking, 2024. 320 pp.
    Science. 2024;386:499.
    PubMed         Abstract available
22. KUPFERSCHMIDT K
    You won’t believe this.
    Science. 2024;386:483-485.
    PubMed         Abstract available

https://etidioh.wordpress.com/2024/11/03/coronavirus-disease-research-references-by-amedeo-nov-3-24/

#betacoronavirus #coronavirus #covid #COVID19 #health #research #sarbecovirus #sarsCov2 #science

Source: Journal of Virology, https://journals.asm.org/doi/10.1128/jvi.01305-24

ABSTRACT
Human-to-human transmission of the highly pathogenic Middle East respiratory syndrome coronavirus (MERS-CoV) is currently inefficient. However, there is concern that the virus might mutate and thereby increase its transmissibility and thus pandemic potential. The pandemic SARS-CoV-2 depends on a highly cleavable furin motif at the S1/S2 site of the viral spike (S) protein for efficient lung cell entry, transmission, and pathogenicity. Here, by employing pseudotyped particles, we investigated whether augmented cleavage at the S1/S2 site also increases MERS-CoV entry into Calu-3 human lung cells. We report that polymorphism T746K at the S1/S2 cleavage site or optimization of the furin motif increases S protein cleavage but not lung cell entry. These findings suggest that, unlike what has been reported for SARS-CoV-2, a highly cleavable S1/S2 site might not augment MERS-CoV infectivity for human lung cells.

____

https://etidioh.wordpress.com/2024/10/29/acquisition-of-a-multibasic-cleavage-site-does-not-increase-mers-cov-entry-into-calu-3-human-lung-cells/

#abstract #betacoronavirus #covid #COVID19 #health #merbecovirus #mersCov #research #sarbecovirus #sarsCov2 #science #vaccine

1. KURITZKES DR
   Remdesivir for Patients Hospitalized with COVID-19: Evidence of Effectiveness from Cohort Studies in the Omicron Era.
   Clin Infect Dis. 2024 Oct 24:ciae515. doi: 10.1093.
   PubMed        
2. WHITE EB, Grant L, Mak J, Olsho L, et al
   Influenza Vaccine Effectiveness Against Illness and Asymptomatic Infection in 2022-2023: A Prospective Cohort Study.
   Clin Infect Dis. 2024 Oct 24:ciae491. doi: 10.1093.
   PubMed         Abstract available
3. KALIL AC, Chandak A, Moore LSP, Ahuja N, et al
   Public Health Benefits of Applying Evidence-Based Best Practices in Managing Patients Hospitalized for COVID-19.
   Clin Infect Dis. 2024 Oct 25:ciae517. doi: 10.1093.
   PubMed         Abstract available

   Emerg Infect Dis

4. BRATCHER A, Kao SY, Chun K, Petropoulos CJ, et al
   Quantitative SARS-CoV-2 Spike Receptor-Binding Domain and Neutralizing Antibody Titers in Previously Infected Persons, United States, January 2021-February 2022.
   Emerg Infect Dis. 2024;30:2352-2361.
   PubMed         Abstract available
5. TAKAYAMA Y, Shimakawa Y, Matsuyama R, Chowell G, et al
   SARS-CoV-2 Infection in School Settings, Okinawa Prefecture, Japan, 2021-2022.
   Emerg Infect Dis. 2024;30:2343-2351.
   PubMed         Abstract available
6. DING K, Naqvi OH, Seeberger RJ, Bratzler DW, et al
   Spatiotemporal Ecologic Analysis of COVID-19 Vaccination Coverage and Outcomes, Oklahoma, USA, February 2020-December 2021.
   Emerg Infect Dis. 2024;30:2333-2342.
   PubMed         Abstract available
7. BURCKHARDT I, Burckhardt F
   Epidemiology of Streptococcus pyogenes Disease before, during, and after COVID-19 Pandemic, Germany, 2005-2023.
   Emerg Infect Dis. 2024;30:2435-2438.
   PubMed         Abstract available

   Infect Control Hosp Epidemiol

8. YAN J, McClure T, Aslam A, Bubb T, et al
   Impact of universal masking in reducing the risk of nosocomial respiratory viruses among people with cancer.
   Infect Control Hosp Epidemiol. 2024 Oct 25:1-5. doi: 10.1017/ice.2024.
   PubMed         Abstract available
9. BRAILITA DM, Soma M, Martinez R, Tyner L, et al
   The impact of statewide educational webinars on infection prevention and control knowledge and policy updates in acute and long-term care facilities during the COVID-19 pandemic: the Nebraska experience.
   Infect Control Hosp Epidemiol. 2024 Oct 23:1-4. doi: 10.1017/ice.2024.
   PubMed         Abstract available
10. SCHRANK GM, O’Hara LM, Pineles L, Popescu S, et al
    A survey of healthcare workers on the acceptance and value of personal protective equipment for patient care.
    Infect Control Hosp Epidemiol. 2024 Oct 23:1-5. doi: 10.1017/ice.2024.
    PubMed         Abstract available
11. IIJIMA K, Osako H, Iwata K
    Comparing the effectiveness of universal admission testing and risk-based testing at emergency admission for preventing nosocomial COVID-19: a multicenter retrospective cohort study in Japan.
    Infect Control Hosp Epidemiol. 2024 Oct 22:1-9. doi: 10.1017/ice.2024.
    PubMed         Abstract available
12. DE-LA-ROSA-MARTINEZ D, Vilar-Compte D, Martinez-Rivera N, Ochoa-Hein E, et al
    Multicenter study on Clostridioides difficile infections in Mexico: exploring the landscape.
    Infect Control Hosp Epidemiol. 2024 Oct 21:1-8. doi: 10.1017/ice.2024.
    PubMed         Abstract available
13. RAY MJ, Furuno JP, Strnad LC, Lofgren ET, et al
    Examining the impact of the COVID-19 pandemic on hospital-associated Clostridioides difficile infection.
    Infect Control Hosp Epidemiol. 2024 Oct 21:1-7. doi: 10.1017/ice.2024.
    PubMed         Abstract available

    Int J Infect Dis

14. AZHAR EI, Velavan TP, Rungsung I, Traore T, et al
    Corrigendum to “Middle East respiratory syndrome coronavirus-a 10-year (2012-2022) global analysis of human and camel infections, genomic sequences, lineages, and geographical origins” [International Journal of Infectious Diseases (2023), volume 131,
    Int J Infect Dis. 2024;149:107261.
    PubMed        

    J Virol

15. SONG X, Li Y, Wang C, Zhao Y, et al
    Efficacy evaluation of a bivalent subunit vaccine against epidemic PEDV heterologous strains with low cross-protection.
    J Virol. 2024 Sep 10:e0130924. doi: 10.1128/jvi.01309.
    PubMed         Abstract available
16. CAILLAVA AJ, Alfonso V, Tejerina Cibello M, Demaria MA, et al
    A vaccine candidate based on baculovirus displaying chikungunya virus E1-E2 envelope confers protection against challenge in mice.
    J Virol. 2024 Oct 23:e0101724. doi: 10.1128/jvi.01017.
    PubMed         Abstract available
17. ZHANG C, Jiang Q, Liu Z, Li N, et al
    SARS-CoV-2 NSP6 reduces autophagosome size and affects viral replication via sigma-1 receptor.
    J Virol. 2024 Oct 24:e0075424. doi: 10.1128/jvi.00754.
    PubMed         Abstract available

    JAMA

18. ANDERER S
    HHS Will Provide Free US-Made COVID-19 Tests to Households.
    JAMA. 2024 Oct 25. doi: 10.1001/jama.2024.21819.
    PubMed        

    Life Sci

19. DOS SANTOS L, Favaroni Mendes Salgado Ribeiro LA, Febba Gomes AC, Azinheira Nobrega Cruz N, et al
    ACE and ACE2 activities and polymorphisms assessment: A populational study from Ipaussu (SP, Brazil) during the COVID-19 pandemic.
    Life Sci. 2024;358:123157.
    PubMed         Abstract available

    MMWR Morb Mortal Wkly Rep

20. MA KC, Castro J, Lambrou AS, Rose EB, et al
    Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron XBB and JN.1 Lineages – United States, May 2023-September 2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:938-945.
    PubMed         Abstract available

https://etidioh.wordpress.com/2024/10/27/coronavirus-disease-research-references-by-amedeo-october-27-24/

#abstract #betacoronavirus #covid #COVID19 #exercise #health #nutrition #prevention #research #sarbecovirus #sarsCov2

Source: Lancet Infectious Diseases, https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00574-7/fulltext?rss=yes

Summary
Background
Existing studies on SARS-CoV-2 infection have mainly focused on severe clinical outcomes; understanding of the clinical severity profile of general community infections is poor. We aimed to assess and compare the clinical profiles of infections with SARS-CoV-2 omicron (B.1.1.529) subvariants in a representative community cohort in Hong Kong during periods of BA.2, BA.4/5, and XBB dominance.

Methods
In this prospective cohort study in Hong Kong, a representative community cohort of individuals aged at least 5 years were recruited by random-digit dialling and underwent weekly rapid antigen testing for SARS-CoV-2, irrespective of symptoms, during three periods from March 1, 2022, to Oct 31, 2023, in which the BA.2, BA.4/5, or XBB subvariants were dominant. We analysed the likelihood of symptoms, as well as the patterns, severity, and duration of symptoms and their associations with participant demographics and vaccination and infection histories.

Findings
1126 (11·0%) of 10 279 participants in the BA.2 period, 830 (6·6%) of 12 588 in the BA.4/5 period, and 633 (11·1%) of 5690 during the XBB period tested positive for SARS-CoV-2 infection on rapid antigen tests. Community infections were generally mild, with asymptomatic infections comprising 22·0–25·0% of infections. No hospitalisations or deaths occurred as a direct result of SARS-CoV-2 infection during the study period. Compared with children aged 5–17 years, a higher likelihood of being symptomatic on infection was found for adults aged 18–59 years during the period of BA.2 dominance and adults aged 60 years or older during XBB dominance. Most (>90·0%) participants with symptomatic infections reported respiratory and systemic symptoms. Up-to-date vaccination with a regimen containing the BNT162b2 vaccine, compared with those without an up-to-date vaccine, was associated with a reduced likelihood of symptoms on infection during the period of BA.2 dominance and of severe symptoms causing substantial disturbance to daily life (grade 3 symptoms) during periods of BA.2 and BA.4/5 dominance, whereas no association was observed during the period of XBB dominance. Previous SARS-CoV-2 infection was associated with a reduced likelihood of symptoms on infection during BA.4/5 and XBB dominance and of severe symptoms during XBB dominance. Reports of severe symptoms increased over the three periods, from 236 (27·7%) of 852 symptomatic participants during BA.2 dominance to 176 (37·1%) of 475 during XBB dominance. The duration of symptoms was longest in the BA.2 period (median 10·0 days [95% CI 9·0–10·0]) and similar in the other two periods (8·0 [8·0–9·0] during BA.4/5 dominance and 8·0 [8·0–9·0] during XBB dominance). A symptom duration of 60 days or longer was reported only during the period of BA.2 dominance, in six (0·7%) of 824 infections.

Interpretation
SARS-CoV-2 infections were generally mild, but not increasingly so, along the evolution of omicron subvariants in this highly vaccinated population. About a third of participants with symptomatic infections reported that the symptoms severely affected daily life even if they were not admitted to hospital, resulting in morbidity, absence from work or school due to illness, productivity loss, and increased medicoeconomic burden. A gradual reduction in the association of vaccines and increase in the association of previous infection with the symptom profile, possibly reflecting the effects of immune escape and waning, were observed over the study period.

____

https://etidioh.wordpress.com/2024/10/15/clinical-profile-analysis-of-sars-cov-2-community-infections-during-periods-with-omicron-ba2-ba4-5-and-xbb-dominance-in-hk-a-prospective-cohort-study/

#abstract #betacoronavirus #coronavirus #covid #COVID19 #health #HKPRCSAR #omicron #research #sarbecovirus #sarsCov2 #vaccine

Source: Nature Communications, https://www.nature.com/articles/s41467-024-52808-2

Abstract
Since 2019, SARS-CoV-2 has undergone mutations, resulting in pandemic and epidemic waves. The SARS-CoV-2 spike protein, crucial for cellular entry, binds to the ACE2 receptor exclusively when its receptor-binding domain (RBD) adopts the up-conformation. However, whether ACE2 also interacts with the RBD in the down-conformation to facilitate the conformational shift to RBD-up remains unclear. Herein, we present the structures of the BA.2.86 and the JN.1 spike proteins bound to ACE2. Notably, we successfully observed the ACE2-bound down-RBD, indicating an intermediate structure before the RBD-up conformation. The wider and mobile angle of RBDs in the up-state provides space for ACE2 to interact with the down-RBD, facilitating the transition to the RBD-up state. The K356T, but not N354-linked glycan, contributes to both of infectivity and neutralizing-antibody evasion in BA.2.86. These structural insights the spike-protein dynamics would help understand the mechanisms underlying SARS-CoV-2 infection and its neutralization.

____

https://etidioh.wordpress.com/2024/10/07/structural-basis-for-receptor-binding-domain-mobility-of-the-spike-in-sars-cov-2-ba286-and-jn1/

#abstract #betacoronavirus #covid #COVID19 #health #research #sarbecovirus #sarsCov2 #science

1. VAN DER HORST D, Carter-Timofte ME, Danneels A, Silva da Costa L, et al
   Large-scale deep learning identifies the antiviral potential of PKI-179 and MTI-31 against coronaviruses.
   Antiviral Res. 2024;231:106012.
   PubMed         Abstract available

   BMJ

2. IACOBUCCI G
   Covid inquiry hears harrowing evidence of effects on ICU staff.
   BMJ. 2024;386:q2125.
   PubMed        
3. NABAVI N
   Mix of relief and disappointment-striking a balance in the pay deal for resident doctors in England.
   BMJ. 2024;386:q2116.
   PubMed        
4. BOUM Y 2ND, Ndembi N
   Mpox needs a locally tailored global response.
   BMJ. 2024;386:q2094.
   PubMed        
5. DARLOW J
   Is the NHS “broken”? Staff haven’t given up, neither should our politicians.
   BMJ. 2024;386:q2130.
   PubMed        
6. DEMASI M
   Journal retracts Covaxin study after manufacturer sues for defamation.
   BMJ. 2024;386:q2119.
   PubMed        
7. Seven days in medicine: 18-24 September 2024.
   BMJ. 2024;386:q2087.
   PubMed        
8. TANNE JH
   Whooping cough: Fivefold rise in US cases spells return to pre-pandemic levels.
   BMJ. 2024;386:q2114.
   PubMed        
9. MAHASE E
   Politicians are failing to prepare for next pandemic, warns head of European health agency.
   BMJ. 2024;386:q2115.
   PubMed        
10. MAHASE E
    Covid inquiry: UKHSA chief is challenged on view that evidence for FFP3 masks is “weak”.
    BMJ. 2024;386:q2075.
    PubMed        

    Clin Infect Dis

11. TRAN KC, Asfar P, Cheng M, Demiselle J, et al
    Effects of Losartan on Patients Hospitalized for Acute COVID-19: A Randomized Controlled Trial.
    Clin Infect Dis. 2024;79:615-625.
    PubMed         Abstract available
12. FONG Y, Dang L, Zhang B, Fintzi J, et al
    Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.
    Clin Infect Dis. 2024 Sep 26:ciae465. doi: 10.1093.
    PubMed         Abstract available
13. Correction to: Changes in the Appropriateness of US Outpatient Antibiotic Prescribing After the COVID-19 Outbreak: An Interrupted Time series Analysis of 2017-2021 Data.
    Clin Infect Dis. 2024 Sep 25:ciae455. doi: 10.1093.
    PubMed        

    Emerg Infect Dis

14. CHARLES H, Thorley K, Turner C, Bennet KF, et al
    Mpox Epidemiology and Vaccine Effectiveness, England, 2023.
    Emerg Infect Dis. 2024;30:2145-2148.
    PubMed         Abstract available
15. WERNIKE K, Mehl C, Aebischer A, Ulrich L, et al
    SARS-CoV-2 and Other Coronaviruses in Rats, Berlin, Germany, 2023.
    Emerg Infect Dis. 2024;30:2205-2208.
    PubMed         Abstract available
16. LININGER N, Falender R, Cieslak P, Novak A, et al
    Correlation between Viral Wastewater Concentration and Respiratory Tests, Oregon, USA.
    Emerg Infect Dis. 2024;30:2194-2196.
    PubMed         Abstract available

    Infect Control Hosp Epidemiol

17. BRANCH-ELLIMAN W, Banach DB, Batshon LJ, Dumyati G, et al
    SHEA position statement on pandemic preparedness for policymakers: pandemic data collection, maintenance, and release.
    Infect Control Hosp Epidemiol. 2024;45:821-825.
    PubMed         Abstract available
18. HSU VP, Pergam SA, Shenoy ES, Banach DB, et al
    SHEA position statement on pandemic preparedness for policymakers: emerging infectious threats.
    Infect Control Hosp Epidemiol. 2024;45:818-820.
    PubMed        
19. DEWITT ME, Sampson MM, Kester S, MacNeill E, et al
    Racial disparities in central line-associated bloodstream infections: the impact of the COVID-19 pandemic.
    Infect Control Hosp Epidemiol. 2024 Sep 26:1-5. doi: 10.1017/ice.2024.
    PubMed         Abstract available

    Int J Infect Dis

20. LEE JA, Jang H, Ahn SM, Seong JE, et al
    Estimates of Vaccine Effectiveness of the Updated Monovalent XBB.1.5 COVID-19 Vaccine Against Symptomatic SARS-CoV-2 Infection, Hospitalization, and Receipt of Oxygen Therapy in South Korea – October 26 to December 31, 2023.
    Int J Infect Dis. 2024 Sep 20:107249. doi: 10.1016/j.ijid.2024.107249.
    PubMed         Abstract available
21. TAKAHASHI H, Morikawa M, Satake Y, Nagamatsu H, et al
    Diagnostic Utility of Pharyngeal Follicular Structures in COVID-19: A Large-scale Cross-Sectional Study.
    Int J Infect Dis. 2024 Sep 21:107244. doi: 10.1016/j.ijid.2024.107244.
    PubMed         Abstract available

    J Infect

22. MCLEOD C, Dymock, Flanagan KL, Plebanski M, et al
    The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-<70 years old.
    J Infect. 2024 Sep 26:106286. doi: 10.1016/j.jinf.2024.106286.
    PubMed         Abstract available
23. VEGA-PIRIS L, Carretero SG, Mayordomo JL, Zarzuelo MBR, et al
    Severity of Respiratory Syncytial Virus compared with SARS-CoV-2 and Influenza among hospitalised adults >/=65 years.
    J Infect. 2024 Sep 26:106292. doi: 10.1016/j.jinf.2024.106292.
    PubMed         Abstract available
24. CHEN X, Balliew J, Bauer CX, Deegan J, et al
    Revealing patterns of SARS-CoV-2 variant emergence and evolution using RBD amplicon sequencing of wastewater.
    J Infect. 2024 Sep 26:106284. doi: 10.1016/j.jinf.2024.106284.
    PubMed         Abstract available
25. RABDANO SO, Ruzanova EA, Vertyachikh AE, Teplykh VA, et al
    N-protein vaccine is effective against COVID-19: phase 3, randomized, double-blind, placebo-controlled clinical trial.
    J Infect. 2024 Sep 26:106288. doi: 10.1016/j.jinf.2024.106288.
    PubMed         Abstract available
26. SABATE-ELABBADI A, Brolon L, Brun-Buisson C, Guillemot D, et al
    Trends in hospitalisations for lower respiratory infections after the COVID-19 pandemic in France.
    J Infect. 2024 Sep 26:106287. doi: 10.1016/j.jinf.2024.106287.
    PubMed         Abstract available

    J Med Virol

27. KUHN D, Heinen N, Sutter K, Herrmann ST, et al
    Divergent autoantibody and cytokine levels in COVID-19 sepsis patients influence survival.
    J Med Virol. 2024;96:e29935.
    PubMed         Abstract available
28. LOVELL JF, Miura K, Baik YO, Lee C, et al
    Interim safety and immunogenicity analysis of the EuCorVac-19 COVID-19 vaccine in a Phase 3 randomized, observer-blind, immunobridging trial in the Philippines.
    J Med Virol. 2024;96:e29927.
    PubMed         Abstract available
29. LI H, Yang Y, Tao R, Shang S, et al
    Analyzing infections caused by 11 respiratory pathogens in children: Pre- and post-COVID-19 pandemic trends in China.
    J Med Virol. 2024;96:e29929.
    PubMed         Abstract available
30. HORI M, Hayama-Terada M, Kitamura A, Hosozawa M, et al
    Risk factors for post-coronavirus disease condition in the Alpha-, Delta-, and Omicron-dominant waves among adults in Japan: A population-based matched case-control study.
    J Med Virol. 2024;96:e29928.
    PubMed         Abstract available

    J Virol

31. KANG JS, Zhou K, Wang H, Tang S, et al
    Architectural organization and in situ fusion protein structure of lymphocytic choriomeningitis virus.
    J Virol. 2024 Sep 27:e0064024. doi: 10.1128/jvi.00640.
    PubMed         Abstract available

    JAMA

32. ANDERER S
    Caseload Strain Contributed to 1 in 5 COVID-19 Deaths at US Hospitals.
    JAMA. 2024 Sep 27. doi: 10.1001/jama.2024.19687.
    PubMed        

    Lancet

33. IMANI-MUSIMWA P, Ververs M
    Mpox and breastmilk: for once, can we act in time?
    Lancet. 2024 Sep 13:S0140-6736(24)01881-6. doi: 10.1016/S0140-6736(24)01881.
    PubMed        
34. HORTON R
    Offline: Xenotransplantation-a new era beckons.
    Lancet. 2024;404:1181.
    PubMed        
35. ROMANELLO M, Costello A
    The Lancet Countdown on health and climate change: competing interests and optimism bias – Authors’ reply.
    Lancet. 2024;404:1197-1198.
    PubMed        
36. BRINK N, Chersich MF
    The Lancet Countdown on health and climate change: competing interests and optimism bias.
    Lancet. 2024;404:1196.
    PubMed        
37. BUTLER CD, Combs Bowles D, Hanigan IC, Harmer A, et al
    The Lancet Countdown on health and climate change: competing interests and optimism bias.
    Lancet. 2024;404:1196-1197.
    PubMed        
38. ROMANELLO M, Beggs PJ, Cai W, Gordon-Strachan G, et al
    The Lancet Countdown on health and climate change: representation matters – Authors’ reply.
    Lancet. 2024;404:1195-1196.
    PubMed        
39. STREET R, Wright CY
    The Lancet Countdown on health and climate change: representation matters.
    Lancet. 2024;404:1194.
    PubMed        

    Lancet Infect Dis

40. DAS M
    Understanding outbreak preparedness.
    Lancet Infect Dis. 2024;24:1079.
    PubMed        
41. OLBRICH L, Franckling-Smith Z, Larsson L, Sabi I, et al
    Sequential and parallel testing for microbiological confirmation of tuberculosis disease in children in five low-income and middle-income countries: a secondary analysis of the RaPaed-TB study.
    Lancet Infect Dis. 2024 Sep 20:S1473-3099(24)00494.
    PubMed         Abstract available
42. LAWSON M
    Globalisation and COVID-19.
    Lancet Infect Dis. 2024 Sep 20:S1473-3099(24)00621.
    PubMed        
43. TERSTAPPEN J, Hak SF, Bhan A, Bogaert D, et al
    The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access.
    Lancet Infect Dis. 2024 Sep 23:S1473-3099(24)00455.
    PubMed         Abstract available
44. FIGUEROA AL, Torres D, Reyes-Acuna C, Matherne P, et al
    Safety and immunogenicity of a single-dose omicron-containing COVID-19 vaccination in adolescents: an open-label, single-arm, phase 2/3 trial.
    Lancet Infect Dis. 2024 Sep 24:S1473-3099(24)00501.
    PubMed         Abstract available
45. WANG WX, Zhu FC
    COVID-19 immunisation strategies for adolescents.
    Lancet Infect Dis. 2024 Sep 24:S1473-3099(24)00563.
    PubMed        
46. HAPPLE C, Hoffmann M, Kempf A, Nehlmeier I, et al
    Humoral immunity after mRNA SARS-CoV-2 omicron JN.1 vaccination.
    Lancet Infect Dis. 2024 Sep 25:S1473-3099(24)00603.
    PubMed        

    MMWR Morb Mortal Wkly Rep

47. HAVERS FP, Whitaker M, Chatwani B, Patton ME, et al
    COVID-19-Associated Hospitalizations and Maternal Vaccination Among Infants Aged <6 Months – COVID-NET, 12 States, October 2022-April 2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:830-836.
    PubMed         Abstract available
48. HILL HA, Yankey D, Elam-Evans LD, Mu Y, et al
    Decline in Vaccination Coverage by Age 24 Months and Vaccination Inequities Among Children Born in 2020 and 2021 – National Immunization Survey-Child, United States, 2021-2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:844-853.
    PubMed         Abstract available

    Nature

49. The youngest among us fight COVID-19 in their own way.
    Nature. 2024 Sep 24. doi: 10.1038/d41586-024-03091.
    PubMed   

https://etidioh.wordpress.com/2024/09/29/coronavirus-disease-research-references-amedeo-september-29-24/

#betacoronavirus #covid #COVID19 #health #pandemic #research #sarbecovirus #sarsCov2 #vaccine

#Universal subunit #vaccine protects against multiple #SARS-CoV-2 #variants and SARS-CoV, npj Vaccines: https://www.nature.com/articles/s41541-024-00922-z

Overall, the designed vaccine has potential for development as a universal #COVID19 vaccine and/or a pan - #sarbecovirus subunit vaccine that will prevent current and future outbreaks caused by SARS-CoV-2 variants and SARS-related CoVs.

1. June 1 Highlight.
   Am J Respir Crit Care Med. 2024;209:xxxvii-xxxviii.
   PubMed        

   BMJ

2. REYNOLDS C, Naqvi H
   Better use of data can help to prevent future deaths.
   BMJ. 2024;385:q1181.
   PubMed        
3. LYNN E
   May top picks: politics, psychological safety, and creativity.
   BMJ. 2024;385:q1166.
   PubMed        
4. TAYLOR L
   Pandemic treaty: panel calls for “reset” to talks as negotiators miss deadline.
   BMJ. 2024;385:q1193.
   PubMed        
5. LIMB M
   Labour’s pledge to clear NHS waiting list within five years will be tough to achieve, say leaders.
   BMJ. 2024;385:q1186.
   PubMed        
6. KMIETOWICZ Z
   Junior doctors in England announce five day walkout ahead of general election.
   BMJ. 2024;385:q1183.
   PubMed        
7. MAHASE E
   GPs could threaten mass resignation over NHS contract.
   BMJ. 2024;385:q1182.
   PubMed        
8. WISE J
   Improving infection prevention could avoid 750 000 deaths a year, say experts.
   BMJ. 2024;385:q1163.
   PubMed        
9. DYER O
   Covid-19: South African disclosures reveal secretive world of nations’ vaccine contracts.
   BMJ. 2024;385:q1172.
   PubMed        

   Clin Infect Dis

10. WOLFE DN, Arangies E, David GL, Armstrong B, et al
    Development of Next-Generation COVID-19 Vaccines: BARDA Supported Phase 2b Study Designs.
    Clin Infect Dis. 2024 May 28:ciae286. doi: 10.1093.
    PubMed         Abstract available
11. HILL JA, Martens MJ, Young JH, Bhavsar K, et al
    SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study.
    Clin Infect Dis. 2024 May 27:ciae291. doi: 10.1093.
    PubMed         Abstract available

    Int J Infect Dis

12. REEKIE J, Stovring H, Nielsen H, Johansen IS, et al
    Development of antibody levels and subsequent decline in individuals with vaccine induced and hybrid immunity to SARS-CoV-2.
    Int J Infect Dis. 2024 May 25:107111. doi: 10.1016/j.ijid.2024.107111.
    PubMed         Abstract available

    Intensive Care Med

13. OUD L
    Long-term outcomes of critically ill patients with hematological malignancies: what is the impact of the coronavirus disease 2019 pandemic?
    Intensive Care Med. 2024 May 28. doi: 10.1007/s00134-024-07493.
    PubMed        

    J Med Virol

14. HAN Y, Ma Y, Wang Z, Feng F, et al
    TMPRSS13 promotes the cell entry of swine acute diarrhea syndrome coronavirus.
    J Med Virol. 2024;96:e29712.
    PubMed         Abstract available
15. BORGOGNA C, Ferrante D, Rosso G, Guglielmetti G, et al
    A prospective humoral immune monitoring study of kidney transplant recipients receiving three doses of SARS-CoV-2 mRNA vaccine.
    J Med Virol. 2024;96:e29710.
    PubMed         Abstract available
16. PAVIA G, Quirino A, Marascio N, Veneziano C, et al
    Persistence of SARS-CoV-2 infection and viral intra- and inter-host evolution in COVID-19 hospitalized patients.
    J Med Virol. 2024;96:e29708.
    PubMed         Abstract available
17. KOW CS, Ramachandram DS, Hasan SS, Thiruchelvam K, et al
    Antibiotics in COVID-19: Unveiling disturbing truths through critical scrutiny.
    J Med Virol. 2024;96:e29720.
    PubMed        
18. CHEN IW, Yu TS, Lin CH, Hung KC, et al
    Effectiveness of nirmatrelvir-ritonavir on severe outcomes of COVID-19: A meta-regression analysis.
    J Med Virol. 2024;96:e29718.
    PubMed        

    J Travel Med

19. TAY M, Lee B, Ismail MH, Yam J, et al
    Usefulness of aircraft and airport wastewater for monitoring multiple pathogens including SARS-CoV-2 variants.
    J Travel Med. 2024 May 30:taae074. doi: 10.1093.
    PubMed         Abstract available

    J Virol

20. MARIZZI C, Ajayi PK, McMahon R, Meade PS, et al
    A community science approach to public health and public trust in science.
    J Virol. 2024 May 29:e0082524. doi: 10.1128/jvi.00825.
    PubMed         Abstract available
21. RAHMAN SM, Buchholz DW, Imbiakha B, Jager MC, et al
    Migraine inhibitor olcegepant reduces weight loss and IL-6 release in SARS-CoV-2-infected older mice with neurological signs.
    J Virol. 2024 May 30:e0006624. doi: 10.1128/jvi.00066.
    PubMed         Abstract available
22. KARMAKAR S, Das Sarma J
    Human coronavirus OC43 infection remodels connexin 43-mediated gap junction intercellular communication in vitro.
    J Virol. 2024 May 31:e0047824. doi: 10.1128/jvi.00478.
    PubMed         Abstract available

    Lancet

23. THORNTON J
    Infected blood report release marks a day of shame for the UK.
    Lancet. 2024;403:2276-2277.
    PubMed        
24. LAXMINARAYAN R, Impalli I, Rangarajan R, Cohn J, et al
    Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance.
    Lancet. 2024 May 20:S0140-6736(24)00878-X. doi: 10.1016/S0140-6736(24)00878.
    PubMed         Abstract available
25. THE LANCET
    Cyberattacks on health care-a growing threat.
    Lancet. 2024;403:2263.
    PubMed        
26. KIMBALL AB, Jemec GBE, Sayed CJ, Kirby JS, et al
    Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
    Lancet. 2024 May 22:S0140-6736(24)00101-6. doi: 10.1016/S0140-6736(24)00101.
    PubMed         Abstract available
27. PATERLINI M
    Warnings over Italian health-care devolution.
    Lancet. 2024;403:2279.
    PubMed        

    Lancet Infect Dis

28. HALL P
    Highlights of ESCMID Global 2024.
    Lancet Infect Dis. 2024;24:e357.
    PubMed        
29. VENKATESAN P
    Alasdair Macintosh Geddes.
    Lancet Infect Dis. 2024;24:577.
    PubMed        

    Life Sci

30. PETRY J, Weiser T, Griesbaum L, Schroder K, et al
    1.8-cineole prevents platelet activation and aggregation by activating the cAMP pathway via the adenosine A(2A) receptor.
    Life Sci. 2024 May 27:122746. doi: 10.1016/j.lfs.2024.122746.
    PubMed         Abstract available

    N Engl J Med

31. WANG JJ, Schonborn L, Warkentin TE, Chataway T, et al
    Antibody Fingerprints Linking Adenoviral Anti-PF4 Disorders.
    N Engl J Med. 2024;390:1827-1829.
    PubMed        
32. HALABI S, Gostin LO, Egbokhare O, Kavanagh MM, et al
    Global Health Law for a Safer and Fairer World.
    N Engl J Med. 2024;390:1925-1931.
    PubMed        

    Nature

33. HAN Y, Duan X, Yang L, Nilsson-Payant BE, et al
    Author Correction: Identification of SARS-CoV-2 inhibitors using lung and colonic organoids.
    Nature. 2024 May 29. doi: 10.1038/s41586-024-07593.
    PubMed        

    Science

34. VAN DER LINDEN S, Kyrychenko Y
    A broader view of misinformation reveals potential for intervention.
    Science. 2024;384:959-960.
    PubMed         Abstract available
35. ALLEN J, Watts DJ, Rand DG
    Quantifying the impact of misinformation and vaccine-skeptical content on Facebook.
    Science. 2024;384:eadk3451.
    PubMed         Abstract available

https://etidioh.wordpress.com/2024/06/01/coronavirus-disease-research-references-by-amedeo-june-1-24/

#betacoronavirus #coronavirus #COVID19 #exercise #health #mentalHealth #nutrition #research #sarbecovirus #sarsCov2 #wellness

1. MELLO MM, Jiang D, Platt E, Moran-McCabe K, et al.
   Legal infrastructure for pandemic response: lessons not learnt in the US.
   BMJ. 2024;384:e076269.
   PubMed: https://www.amedeo.com/p2.php?id=38346813&s=cov&pm=2
    
   Share: https://m.amedeo.com/38346813
2. Seven days in medicine: 31 Jan to 6 Feb 2024.
   BMJ. 2024;384:q299.
   PubMed: https://www.amedeo.com/p2.php?id=38331441&s=cov&pm=2
    
   Share: https://m.amedeo.com/38331441
3. IACOBUCCI G.
   Long covid: Online rehabilitation can improve quality of life, study reports.
   BMJ. 2024;384:q346.
   PubMed: https://www.amedeo.com/p2.php?id=38331437&s=cov&pm=2
    
   Share: https://m.amedeo.com/38331437
4. COLSON P, Delerce J, Pontarotti P, Devaux C, et al.
   Resistance-associated mutations to the anti-SARS-CoV-2 agent nirmatrelvir:
   Selection not induction.
   J Med Virol. 2024;96:e29462.
   PubMed: https://www.amedeo.com/p2.php?id=38363015&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38363015
5. SADAT LARIJANI M, Javadi A, Eskandari SE, Doroud D, et al.
   The impact of ABO blood types on humoral immunity responses and antibody
   persistency after different COVID-19 vaccine regimens.
   J Med Virol. 2024;96:e29438.
   PubMed: https://www.amedeo.com/p2.php?id=38353517&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38353517
6. CENAT JM, Farahi SMMM, Dalexis RD, Yaya S, et al.
   COVID-19 vaccine uptake, conspiracy theories, and health literacy among Black
   individuals in Canada: Racial discrimination, confidence in health, and COVID-19
   stress as mediators.
   J Med Virol. 2024;96:e29467.
   PubMed: https://www.amedeo.com/p2.php?id=38348886&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38348886
7. KWOK KO, Wei WI, Mcneil EB, Tang A, et al.
   Comparative analysis of symptom profile and risk of death associated with
   infection by SARS-CoV-2 and its variants in Hong Kong.
   J Med Virol. 2024;96:e29326.
   PubMed: https://www.amedeo.com/p2.php?id=38345166&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38345166
8. KIM D, Kim M, Kim J, Baek K, et al.
   A mouse xenograft long-term replication yields a SARS-CoV-2 Delta mutant with
   increased lethality.
   J Med Virol. 2024;96:e29459.
   PubMed: https://www.amedeo.com/p2.php?id=38345153&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38345153
9. ZHAN H, Xie Y, Liu Y, Cheng L, et al.
   Omicron BA.4/5 neutralization and cell-mediated immune responses in relation to
   baseline immune status and breakthrough infection among PLWH: A follow-up cohort
   study.
   J Med Virol. 2024;96:e29446.
   PubMed: https://www.amedeo.com/p2.php?id=38345110&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38345110
10. ZENG G, Zhang Z, Wang L, Li J, et al.
    Risk factors of long COVID 6-12 months after infection with the Omicron variant
    among nonhospitalized patients.
    J Med Virol. 2023;95:e29235.
    PubMed: https://www.amedeo.com/p2.php?id=37970745&s=cov&pm=2
     
    Share: https://m.amedeo.com/37970745
11. LI Z, Lai Y, Qiu R, Tang W, et al.
    Hyperacetylated microtubules assist porcine deltacoronavirus nsp8 to degrade MDA5
    via SQSTM1/p62-dependent selective autophagy.
    J Virol. 2024 Feb 14:e0000324. doi: 10.1128/jvi.00003.
    PubMed: https://www.amedeo.com/p2.php?id=38353538&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38353538
12. RUBIN R.
    When It Comes to SARS-CoV-2 Clearance, People Who are Immunocompromised Are Not
    All Alike.
    JAMA. 2024 Feb 14. doi: 10.1001/jama.2024.1014.
    PubMed: https://www.amedeo.com/p2.php?id=38353960&s=cov&pm=2
     
    Share: https://m.amedeo.com/38353960
13. WALLER BY, Joseph VA, Keyes KM.
    Racial inequities in homicide rates and homicide methods among Black and White
    women aged 25-44 years in the USA, 1999-2020: a cross-sectional time series
    study.
    Lancet. 2024 Feb 8:S0140-6736(23)02279-1. doi: 10.1016/S0140-6736(23)02279.
    PubMed: https://www.amedeo.com/p2.php?id=38342127&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38342127
14. VERMERSCH P, Granziera C, Mao-Draayer Y, Cutter G, et al.
    Inhibition of CD40L with Frexalimab in Multiple Sclerosis.
    N Engl J Med. 2024;390:589-600.
    PubMed: https://www.amedeo.com/p2.php?id=38354138&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38354138
15. The immune markers that predict who can keep SARS-CoV-2 in check.
    Nature. 2024 Feb 13. doi: 10.1038/d41586-024-00411.
    PubMed: https://www.amedeo.com/p2.php?id=38351161&s=cov&pm=2
     
    Share: https://m.amedeo.com/38351161
16. GAGLIARDINI R, Giacomelli A, Bozzi G, D’Arminio Monforte A, et al.
    Impact of COVID-19 pandemic on retention in care of native and migrant people
    with HIV in the ICONA cohort.
    Travel Med Infect Dis. 2024;58:102691.
    PubMed: https://www.amedeo.com/p2.php?id=38336335&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38336335
17. HOFMEYER KA, Ventura CL, Armstrong KL, Houchens CR, et al.
    Project NexGen: Developing the Next Generation of COVID-19 Vaccines and
    Therapeutics to Respond to the Present and Prepare for the Future.
    Clin Infect Dis. 2024 Feb 13:ciae073. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=38356144&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38356144
18. MACHKOVECH HM, Hahn AM, Garonzik Wang J, Grubaugh ND, et al.
    Persistent SARS-CoV-2 infection: significance and implications.
    Lancet Infect Dis. 2024 Feb 7:S1473-3099(23)00815.
    PubMed: https://www.amedeo.com/p2.php?id=38340735&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38340735
19. JIAO Z, Wang P, Hu X, Chen Y, et al.
    Feline infectious peritonitis virus ORF7a is a virulence factor involved in
    inflammatory pathology in cats.
    Antiviral Res. 2024;222:105794.
    PubMed: https://www.amedeo.com/p2.php?id=38176470&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38176470

https://etidioh.wordpress.com/2024/02/18/coronavirus-disease-research-references-by-amedeo-february-18-24/

#betacoronavirus #coronavirus #covid #COVID19 #health #research #sarbecovirus #sarsCov2 #science

1. BOUZIDI HS, Driouich JS, Klitting R, Bernadin O, et al
   Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains.
   Antiviral Res. 2024 Jan 23:105814. doi: 10.1016/j.antiviral.2024.105814.
   PubMed         Abstract available
2. BOGACHEVA MS, Kuivanen S, Potdar S, Hassinen A, et al
   Drug repurposing platform for deciphering the druggable SARS-CoV-2 interactome.
   Antiviral Res. 2024 Jan 23:105813. doi: 10.1016/j.antiviral.2024.105813.
   PubMed         Abstract available
3. BOND ACS, Crocker MA, Wilczek MP, DuShane JK, et al
   High-throughput drug screen identifies calcium and calmodulin inhibitors that reduce JCPyV infection.
   Antiviral Res. 2024 Jan 19:105817. doi: 10.1016/j.antiviral.2024.105817.
   PubMed         Abstract available
4. IDRIS A, Supramaniam A, Tayyar Y, Kelly G, et al
   An intranasally delivered ultra-conserved siRNA prophylactically represses SARS-CoV-2 infection in the lung and nasal cavity.
   Antiviral Res. 2024;222:105815.
   PubMed         Abstract available

   BMJ

5. WATERS A
   Covid-19: Doctors instruct law firm in bid for compensation after developing long covid.
   BMJ. 2024;384:q188.
   PubMed        
6. BRINDLEY P
   Essential workers during covid-19: how quickly we forget.
   BMJ. 2024;384:q179.
   PubMed        
7. WISE J
   UK covid inquiry: Scotland’s infection control and care home policies face scrutiny.
   BMJ. 2024;384:q162.
   PubMed        

   Clin Infect Dis

8. RYBOLT L, Oehler RL, Khalil FK, Khalil B, et al
   A 22-Year-Old With a Left Apical Chest Mass.
   Clin Infect Dis. 2024;78:199-201.
   PubMed        
9. HSUEH K, Teherani A, Guzman-Cottrill JA
   The Leaders in Epidemiology, Antimicrobial Stewardship, and Public Health (LEAP) Fellowship, a Novel Training Program in Public Health for Infectious Diseases Physicians.
   Clin Infect Dis. 2024 Jan 24:ciad787. doi: 10.1093.
   PubMed         Abstract available

   Emerg Infect Dis

10. JUSTMAN J, Skalland T, Moore A, Amos CI, et al
    Prevalence of SARS-CoV-2 Infection among Children and Adults in 15 US Communities, 2021(1).
    Emerg Infect Dis. 2024;30:245-254.
    PubMed         Abstract available
11. PORTER SM, Hartwig AE, Bielefeldt-Ohmann H, Marano JM, et al
    Experimental SARS-CoV-2 Infection of Elk and Mule Deer.
    Emerg Infect Dis. 2024;30:354-357.
    PubMed         Abstract available
12. TORI ME, Chontos-Komorowski J, Stacy J, Lamson DM, et al
    Identification of Large Adenovirus Infection Outbreak at University by Multipathogen Testing, South Carolina, USA, 2022.
    Emerg Infect Dis. 2024;30:358-362.
    PubMed         Abstract available
13. TAKEMURA T, Ankhanbaatar U, Settypalli TBK, Purevtseren D, et al
    SARS-CoV-2 Infection in Beaver Farm, Mongolia, 2021.
    Emerg Infect Dis. 2024;30:391-394.
    PubMed         Abstract available
14. HODGES NF, Sparrer M, Sherman T, Mayer T, et al
    Integrating Veterinary Diagnostic Laboratories for Emergency Use Testing during Pandemics(1).
    Emerg Infect Dis. 2024;30:386-388.
    PubMed         Abstract available

    J Infect

15. LIU Y, Sun R, Zhang H, Huang J, et al
    Trends and predictions of tuberculosis notification in mainland China during and after the COVID-19 pandemic.
    J Infect. 2023;87:e100-e103.
    PubMed        
16. AO G, Li T, Nasr B, Wang Y, et al
    The effect of dupilumab on clinical outcomes in patients with COVID-19: A meta-analysis.
    J Infect. 2023;87:e107-e109.
    PubMed        
17. MURRAY JM, Murray DD, Schvoerer E, Akand EH, et al
    SARS-CoV-2 Delta and Omicron community transmission networks as added value to contact tracing.
    J Infect. 2024 Jan 17:S0163-4453(24)00023-9. doi: 10.1016/j.jinf.2024.
    PubMed         Abstract available

    J Med Virol

18. YANG X, Wang Y, Liang Z, Cui T, et al
    Immune escape of BA.2.86 is comparable to XBB subvariants from the plasma of BA.5- and BA.5-XBB-convalescent subpopulations.
    J Med Virol. 2024;96:e29417.
    PubMed         Abstract available
19. ZHANG T, Magazine N, McGee MC, Carossino M, et al
    Th2 and Th17-associated immunopathology following SARS-CoV-2 breakthrough infection in Spike-vaccinated ACE2-humanized mice.
    J Med Virol. 2024;96:e29408.
    PubMed         Abstract available
20. JIA J, Garbarino E, Wang Y, Li J, et al
    Generation of SARS-CoV-2 spike receptor binding domain mutants and functional screening for immune evaders using a novel lentivirus-based system.
    J Med Virol. 2024;96:e29425.
    PubMed         Abstract available
21. SUN Y, Zhou J, Nie W, Tian D, et al
    Study on the epidemiological characteristics of enterovirus among pediatric patients in Hangzhou, China: A comparison between the pre-COVID-19, COVID-19 pandemic, and post-COVID-19 periods.
    J Med Virol. 2024;96:e29412.
    PubMed         Abstract available

    J Travel Med

22. CHIU NC, Chi H, Weng SL, Lin CY, et al
    Unprecedented dengue outbreak in Taiwan following COVID-19.
    J Travel Med. 2024 Jan 21:taae015. doi: 10.1093.
    PubMed        
23. SOHAIL A, Anders KL, McGuinness SL, Leder K, et al
    The epidemiology of imported and locally-acquired dengue in Australia, 2012-2022.
    J Travel Med. 2024 Jan 18:taae014. doi: 10.1093.
    PubMed         Abstract available

    J Virol

24. DEY S, Mondal A
    Unveiling the role of host kinases at different steps of influenza A virus life cycle.
    J Virol. 2024 Jan 4:e0119223. doi: 10.1128/jvi.01192.
    PubMed         Abstract available
25. ZHANG S, Wang J, Liu X, Kan Z, et al
    Pemetrexed alleviates piglet diarrhea by blocking the interaction between porcine epidemic diarrhea virus nucleocapsid protein and Ezrin.
    J Virol. 2024;98:e0162523.
    PubMed         Abstract available

    Lancet

26. MCCLOSKEY B, Saito T, Shimada S, Ikenoue C, et al
    The Tokyo 2020 and Beijing 2022 Olympic Games held during the COVID-19 pandemic: planning, outcomes, and lessons learnt.
    Lancet. 2024 Jan 17:S0140-6736(23)02635-1. doi: 10.1016/S0140-6736(23)02635.
    PubMed         Abstract available

    MMWR Morb Mortal Wkly Rep

27. MONACH PA, Anand ST, Fillmore NR, La J, et al
    Underuse of Antiviral Drugs to Prevent Progression to Severe COVID-19 – Veterans Health Administration, March-September 2022.
    MMWR Morb Mortal Wkly Rep. 2024;73:57-61.
    PubMed         Abstract available

    N Engl J Med

28. BORGHESI A, Casanova JL
    Convalescent Plasma for Covid-19-Induced ARDS.
    N Engl J Med. 2024;390:384-385.
    PubMed        
29. SENEFELD JW, Henderson JP, Joyner MJ
    Convalescent Plasma for Covid-19-Induced ARDS.
    N Engl J Med. 2024;390:385.
    PubMed        
30. CASADEVALL A, Shoham S, Pirofski LA
    Convalescent Plasma for Covid-19-Induced ARDS.
    N Engl J Med. 2024;390:385-386.
    PubMed        
31. MISSET B, Desmecht D, Laterre PF
    Convalescent Plasma for Covid-19-Induced ARDS. Reply.
    N Engl J Med. 2024;390:386.
    PubMed        

    Radiology

32. LEE JE, Jin KN, Hong H, Jeong YJ, et al
    Effectiveness of COVID-19 Vaccines Over Time Against Clinical and Radiologic Outcomes Related to Severe SARS-CoV-2 Infection.
    Radiology. 2024;310:e231928.
    PubMed         Abstract available
33. WELLS AU
    COVID-19 Vaccine Efficacy Over Time: Severe Disease in Hospitalized Patients.
    Radiology. 2024;310:e233340.
    PubMed        

    Science

34. RUF W
    Immune damage in Long Covid.
    Science. 2024;383:262-263.
    PubMed         Abstract available
35. LESLIE M
    SARS-CoV-2 sneezing explained.
    Science. 2024;383:354.
    PubMed         Abstract available

https://etidioh.wordpress.com/2024/01/29/coronavirus-disease-research-references-by-amedeo-january-29-24/

#betacoronavirus #coronavirus #covid #COVID19 #health #research #sarbecovirus #sarsCov2 #science

1. KERCHBERGER VE.
   Host Response to Infection: Not All Lymphopenia Is Created Equal in SARS-CoV-2.
   Am J Respir Crit Care Med. 2024 Jan 8. doi: 10.1164/rccm.202312-2265.
   PubMed: https://www.amedeo.com/p2.php?id=38190496&s=cov&pm=2
    
   Share: https://m.amedeo.com/38190496
2. WU Q, Tong J, Zhang B, Zhang D, et al.
   Real-World Effectiveness of BNT162b2 Against Infection and Severe Diseases in Children and Adolescents.
   Ann Intern Med. 2024 Jan 9. doi: 10.7326/M23-1754.
   PubMed: https://www.amedeo.com/p2.php?id=38190711&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38190711
3. O’DOWD A.
   Covid-19 has cut UK life expectancy by around half a year, data suggest.
   BMJ. 2024;384:q78.
   PubMed: https://www.amedeo.com/p2.php?id=38216221&s=cov&pm=2
    
   Share: https://m.amedeo.com/38216221
4. MAHASE E.
   Covid-19: NICE plans to expand Paxlovid eligibility to 1.4 million more people.
   BMJ. 2024;384:q59.
   PubMed: https://www.amedeo.com/p2.php?id=38212056&s=cov&pm=2
    
   Share: https://m.amedeo.com/38212056
5. Update to living systematic review on SARS-CoV-2 positivity in offspring and timing of mother-to-child transmission.
   BMJ. 2024;384:p2929.
   PubMed: https://www.amedeo.com/p2.php?id=38199645&s=cov&pm=2
    
   Share: https://m.amedeo.com/38199645
6. SLAUNWHITE A, Min JE, Palis H, Urbanoski K, et al.
   Effect of Risk Mitigation Guidance opioid and stimulant dispensations on mortality and acute care visits during dual public health emergencies: retrospective cohort study.
   BMJ. 2024;384:e076336.
   PubMed: https://www.amedeo.com/p2.php?id=38199614&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38199614
7. TANNE JH.
   Covid-19: Some US states and hospitals recommend masks again.
   BMJ. 2024;384:q26.
   PubMed: https://www.amedeo.com/p2.php?id=38182176&s=cov&pm=2
    
   Share: https://m.amedeo.com/38182176
8. EGBELOWO OF, Fox SJ, Gibson GC, Meyers LA, et al.
   Model for Interpreting Discordant SARS-CoV-2 Diagnostic Test Results.
   Emerg Infect Dis. 2024;30.
   PubMed: https://www.amedeo.com/p2.php?id=38217064&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38217064
9. EALES O, Plank MJ, Cowling BJ, Howden BP, et al.
   Key Challenges for Respiratory Virus Surveillance while Transitioning out of Acute Phase of COVID-19 Pandemic.
   Emerg Infect Dis. 2024;30.
   PubMed: https://www.amedeo.com/p2.php?id=38190760&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38190760
10. JEON S, Watson-Lewis L, Rainisch G, Chiu CC, et al.
    Adapting COVID-19 Contact Tracing Protocols to Accommodate Resource Constraints, Philadelphia, Pennsylvania, USA, 2021.
    Emerg Infect Dis. 2024;30.
    PubMed: https://www.amedeo.com/p2.php?id=38181801&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38181801
11. BAI Y, Du Z, Wang L, Lau EHY, et al.
    Public Health Impact of Paxlovid as Treatment for COVID-19, United States.
    Emerg Infect Dis. 2024;30.
    PubMed: https://www.amedeo.com/p2.php?id=38181800&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38181800
12. HU L, Yang Y, Lin J, Yan Q, et al.
    Epidemiological characteristics of respiratory syncytial virus infection in pediatric patients before, during the COVID-19 pandemic and after easing of COVID-19 restrictive measures in China.
    J Med Virol. 2024;96:e29374.
    PubMed: https://www.amedeo.com/p2.php?id=38197487&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38197487
13. ZHANG Y, Ma Y, Sun W, Zhou X, et al.
    Exploring gut-lung axis crosstalk in SARS-CoV-2 infection: Insights from a hACE2 mouse model.
    J Med Virol. 2024;96:e29336.
    PubMed: https://www.amedeo.com/p2.php?id=38193530&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38193530
14. FAVRESSE J, Gillot C, Closset M, Cabo J, et al.
    Durability of humoral and cellular immunity six months after the BNT162b2 bivalent booster.
    J Med Virol. 2024;96:e29365.
    PubMed: https://www.amedeo.com/p2.php?id=38185981&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38185981
15. CHOI CY, Gadhave K, Villano J, Pekosz A, et al.
    Generation and characterization of a humanized ACE2 mouse model to study long-term impacts of SARS-CoV-2 infection.
    J Med Virol. 2024;96:e29349.
    PubMed: https://www.amedeo.com/p2.php?id=38185937&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38185937
16. LEE HM, Shih PC, Wei JC.
    Comment on Shao et al.’s “Risk factors associated with COVID-19 pneumonia in Chinese patients with pre-existing interstitial lung disease during the SARS-CoV-2 pandemic”.
    J Med Virol. 2024;96:e29383.
    PubMed: https://www.amedeo.com/p2.php?id=38180246&s=cov&pm=2
     
    Share: https://m.amedeo.com/38180246
17. LI J, Zhang K, Lin G, Li J, et al.
    CRISPR-Cas system: A promising tool for rapid detection of SARS-CoV-2 variants.
    J Med Virol. 2024;96:e29356.
    PubMed: https://www.amedeo.com/p2.php?id=38180237&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38180237
18. CAPELLI N, Domitien Payet L, Alcocer Cordellat C, Pisoni A, et al.
    SARS-CoV-2 nucleocapsid antigen in plasma of children hospitalized for COVID-19 or with incidental detection of SARS-CoV-2 infection.
    J Med Virol. 2024;96:e29358.
    PubMed: https://www.amedeo.com/p2.php?id=38180230&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38180230
19. MOORE JE, Millar BC.
    Improving health literacy of passengers of cruise ships: readability of passenger-facing COVID-19 information provided by commercial cruise lines-an infodemiology study.
    J Travel Med. 2024 Jan 11:taae006. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=38206876&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38206876
20. JAMES ER, Church LWP, Hoffman SL, Robertson BD, et al.
    Piloting delivery of PfSPZ vaccines for malaria through a cryogenic vaccine cold chain to travel and military medicine clinics.
    J Travel Med. 2024 Jan 11:taae007. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=38206875&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38206875
21. DULIN H, Barre RS, Xu D, Neal A, et al.
    Harnessing preexisting influenza virus-specific immunity increases antibody responses against SARS-CoV-2.
    J Virol. 2024 Jan 11:e0157123. doi: 10.1128/jvi.01571.
    PubMed: https://www.amedeo.com/p2.php?id=38206036&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38206036
22. BERTZBACH LD, Seddar L, von Stromberg K, Ip W-H, et al.
    The adenovirus DNA-binding protein DBP.
    J Virol. 2024 Jan 10:e0188523. doi: 10.1128/jvi.01885.
    PubMed: https://www.amedeo.com/p2.php?id=38197632&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38197632
23. YIN L, Liu X, Yao Y, Yuan M, et al.
    Gut microbiota-derived butyrate promotes coronavirus TGEV infection through impairing RIG-I-triggered local type I interferon responses via class I HDAC inhibition.
    J Virol. 2024 Jan 10:e0137723. doi: 10.1128/jvi.01377.
    PubMed: https://www.amedeo.com/p2.php?id=38197629&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38197629
24. RUBIN R.
    As COVID-19 Cases Surge, Here’s What to Know About JN.1, the Latest SARS-CoV-2 “Variant of Interest”.
    JAMA. 2024 Jan 12. doi: 10.1001/jama.2023.27841.
    PubMed: https://www.amedeo.com/p2.php?id=38214935&s=cov&pm=2
     
    Share: https://m.amedeo.com/38214935
25. RUBIN R.
    From “Immunity Debt” to “Immunity Theft”-How COVID-19 Might Be Tied to Recent Respiratory Disease Surges.
    JAMA. 2024 Jan 10. doi: 10.1001/jama.2023.26608.
    PubMed: https://www.amedeo.com/p2.php?id=38198193&s=cov&pm=2
     
    Share: https://m.amedeo.com/38198193
26. KAPOOR N, Dietz C, Buettner BP.
    An Incarcerated Individual With Weight Loss and Interstitial Pulmonary Infiltrates.
    JAMA. 2024 Jan 8. doi: 10.1001/jama.2023.24260.
    PubMed: https://www.amedeo.com/p2.php?id=38190148&s=cov&pm=2
     
    Share: https://m.amedeo.com/38190148
27. MARKS P, Califf R.
    Is Vaccination Approaching a Dangerous Tipping Point?
    JAMA. 2024 Jan 5. doi: 10.1001/jama.2023.27685.
    PubMed: https://www.amedeo.com/p2.php?id=38180773&s=cov&pm=2
     
    Share: https://m.amedeo.com/38180773
28. PAYNE AB, Novosad S, Wiegand RE, Najdowski M, et al.
    Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing COVID-19-Related Thromboembolic Events Among Medicare Enrollees Aged >/=65 Years and Those with End Stage Renal Disease – United States, September 2022-March 2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:16-23.
    PubMed: https://www.amedeo.com/p2.php?id=38206877&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38206877
29. CHA MJ, Solomon JJ, Lee JE, Choi H, et al.
    Chronic Lung Injury after COVID-19 Pneumonia: Clinical, Radiologic, and Histopathologic Perspectives.
    Radiology. 2024;310:e231643.
    PubMed: https://www.amedeo.com/p2.php?id=38193836&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38193836
30. COHEN J.
    Covid’s cold cousins.
    Science. 2024;383:141-145.
    PubMed: https://www.amedeo.com/p2.php?id=38207045&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38207045
31. NACHMAN S, Aldrovandi G.
    Breastfeeding in the United States Among Women With HIV: Con Viewpoint.
    Clin Infect Dis. 2024 Jan 8:ciad778. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=38185124&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38185124
32. COSSMANN A, Hoffmann M, Stankov MV, Lurken K, et al.
    Immune responses following BNT162b2 XBB.1.5 vaccination in patients on haemodialysis in Germany.
    Lancet Infect Dis. 2024 Jan 8:S1473-3099(23)00783.
    PubMed: https://www.amedeo.com/p2.php?id=38211602&s=cov&pm=2
     
    Share: https://m.amedeo.com/38211602
33. KOSUGI Y, Kaku Y, Hinay AA Jr, Guo Z, et al.
    Antiviral humoral immunity against SARS-CoV-2 omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals.
    Lancet Infect Dis. 2024 Jan 8:S1473-3099(23)00784.
    PubMed: https://www.amedeo.com/p2.php?id=38211599&s=cov&pm=2
     
    Share: https://m.amedeo.com/38211599
34. HANSEN CH, Moustsen-Helms IR, Rasmussen M, Soborg B, et al.
    Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine against hospitalisation in Denmark: a national cohort study.
    Lancet Infect Dis. 2024 Jan 5:S1473-3099(23)00746.
    PubMed: https://www.amedeo.com/p2.php?id=38190834&s=cov&pm=2
     
    Share: https://m.amedeo.com/38190834
35. KAKU Y, Okumura K, Padilla-Blanco M, Kosugi Y, et al.
    Virological characteristics of the SARS-CoV-2 JN.1 variant.
    Lancet Infect Dis. 2024 Jan 3:S1473-3099(23)00813.
    PubMed: https://www.amedeo.com/p2.php?id=38184005&s=cov&pm=2
     
    Share: https://m.amedeo.com/38184005
36. GOVEDNIK T, Lainscek D, Kuhar U, Lachish M, et al.
    TXM peptides inhibit SARS-CoV-2 infection, syncytia formation, and lower inflammatory consequences.
    Antiviral Res. 2024 Jan 9:105806. doi: 10.1016/j.antiviral.2024.105806.
    PubMed: https://www.amedeo.com/p2.php?id=38211737&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38211737
37. GARCIA-RODRIGUEZ I, Moreni G, Capendale PE, Mulder L, et al.
    Assessment of the broad-spectrum host targeting antiviral efficacy of halofuginone hydrobromide in human airway, intestinal and brain organotypic models.
    Antiviral Res. 2024 Jan 6:105798. doi: 10.1016/j.antiviral.2024.105798.
    PubMed: https://www.amedeo.com/p2.php?id=38190972&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38190972

https://etidioh.wordpress.com/2024/01/14/coronavirus-disease-research-references-by-amedeo-january-14-24/

#betacoronavirus #coronavirus #covid #COVID19 #health #research #sarbecovirus #sarsCov2

1. NGO B, Rendell MS.
   Major Update: Masks for Prevention of SARS-CoV-2 in Health Care and Community
   Settings.
   Ann Intern Med. 2023;176:eL230358.
   PubMed: https://www.amedeo.com/p2.php?id=38109756&s=cov&pm=2
    
   Share: https://m.amedeo.com/38109756
2. BROWN TS, Mohareb AM, LaRocque RC.
   Universal Masking in Health Care Settings.
   Ann Intern Med. 2023;176:eL230347.
   PubMed: https://www.amedeo.com/p2.php?id=38109751&s=cov&pm=2
    
   Share: https://m.amedeo.com/38109751
3. REZNICK SE.
   Universal Masking in Health Care Settings.
   Ann Intern Med. 2023;176:eL230346.
   PubMed: https://www.amedeo.com/p2.php?id=38109749&s=cov&pm=2
    
   Share: https://m.amedeo.com/38109749
4. JIRMANUS LZ, Schwartzmann EG, Davids JD, Gullette MM, et al.
   Universal Masking in Health Care Settings.
   Ann Intern Med. 2023;176:eL230350.
   PubMed: https://www.amedeo.com/p2.php?id=38109748&s=cov&pm=2
    
   Share: https://m.amedeo.com/38109748
5. SHENOY ES, Doron S, Branch-Elliman W.
   Universal Masking in Health Care Settings.
   Ann Intern Med. 2023;176:eL230351.
   PubMed: https://www.amedeo.com/p2.php?id=38109747&s=cov&pm=2
    
   Share: https://m.amedeo.com/38109747
6. GAFFNEY A, Himmelstein DU, Woolhandler S.
   Asthma Disparities in the United States Narrowed During the COVID-19 Pandemic:
   Findings From a National Survey, 2019 to 2022.
   Ann Intern Med. 2023 Dec 19. doi: 10.7326/M23-2100.
   PubMed: https://www.amedeo.com/p2.php?id=38109736&s=cov&pm=2
    
   Share: https://m.amedeo.com/38109736
7. LOOI MK.
   Covid-19: WHO adds JN.1 as new variant of interest.
   BMJ. 2023;383:p2975.
   PubMed: https://www.amedeo.com/p2.php?id=38128957&s=cov&pm=2
    
   Share: https://m.amedeo.com/38128957
8. ALTMANN DM, Pagel C.
   Long covid: where are we, what does it say about our pandemic response, and where
   next?
   BMJ. 2023;383:p2972.
   PubMed: https://www.amedeo.com/p2.php?id=38114255&s=cov&pm=2
    
   Share: https://m.amedeo.com/38114255
9. IACOBUCCI G.
   Flu and covid levels rise in England.
   BMJ. 2023;383:p2965.
   PubMed: https://www.amedeo.com/p2.php?id=38114251&s=cov&pm=2
    
   Share: https://m.amedeo.com/38114251
10. IACOBUCCI G.
    Covid-19: Bereaved families group collects BMJ award for holding ministers to
    account.
    BMJ. 2023;383:2955.
    PubMed: https://www.amedeo.com/p2.php?id=38101907&s=cov&pm=2
     
    Share: https://m.amedeo.com/38101907
11. BALABAN N, Mohyuddin GR, Kashi A, Massarweh A, et al.
    Projecting complete redaction of clinical trial protocols (RAPTURE): redacted
    cross sectional study.
    BMJ. 2023;383:e077329.
    PubMed: https://www.amedeo.com/p2.php?id=38097263&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38097263
12. IACOBUCCI G.
    Covid inquiry: What did Johnson say about underestimated risks, excess deaths,
    and his missing WhatsApps?
    BMJ. 2023;383:2914.
    PubMed: https://www.amedeo.com/p2.php?id=38081644&s=cov&pm=2
     
    Share: https://m.amedeo.com/38081644
13. LIU W, Gong F, Zheng X, Pei L, et al.
    Factors associated with prolonged viral shedding of SARS-CoV-2 Omicron variant
    infection in Shanghai: A multicenter, retrospective, observational study.
    J Med Virol. 2023;95:e29342.
    PubMed: https://www.amedeo.com/p2.php?id=38130170&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38130170
14. LEE DH, Han E, Ryu S, Choi HJ, et al.
    Clinical performance of the STANDARD M10 SARS-CoV-2 rapid RT-PCR assay in
    patients visiting an emergency department.
    J Med Virol. 2023;95:e29330.
    PubMed: https://www.amedeo.com/p2.php?id=38117224&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38117224
15. KAPUSTA J, Babicki M, Pieniawska-Smiech K, Kaluzinska-Kolat Z, et al.
    Clinical and electrocardiographic correlates of myocardial dysfunction after
    COVID-19 in nonhospitalised patients in long-term follow-up. Data from the polish
    long-covid cardiovascular study.
    J Med Virol. 2023;95:e29331.
    PubMed: https://www.amedeo.com/p2.php?id=38112151&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38112151
16. ZHOU Y, Liu Y, Jiang L, Zhang R, et al.
    Azvudine and nirmatrelvir-ritonavir in hospitalized patients with
    moderate-to-severe COVID-19: Emulation of a randomized target trial.
    J Med Virol. 2023;95:e29318.
    PubMed: https://www.amedeo.com/p2.php?id=38112106&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38112106
17. SULLIVAN DJ, Focosi D, Hanley DF, Cruciani M, et al.
    Outpatient randomized controlled trials to reduce COVID-19 hospitalization:
    Systematic review and meta-analysis.
    J Med Virol. 2023;95:e29310.
    PubMed: https://www.amedeo.com/p2.php?id=38105461&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38105461
18. LI Y, Yamamoto S, Horii K, Mizoue T, et al.
    Long COVID during the Omicron predominant waves among Japanese healthcare
    workers.
    J Med Virol. 2023;95:e29322.
    PubMed: https://www.amedeo.com/p2.php?id=38103017&s=cov&pm=2
     
    Share: https://m.amedeo.com/38103017
19. FEGHOUL L, Caillault A, Peyrony O, Salmona M, et al.
    Respiratory torque teno virus load at emergency department visit predicts
    intensive care unit admission of SARS-CoV-2 infected patients.
    J Med Virol. 2023;95:e29319.
    PubMed: https://www.amedeo.com/p2.php?id=38102899&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38102899
20. ALLEL K, Cabada MM, Lau C, Mills D, et al.
    Causes of death among international travellers in Peru, 2017 to 2021.
    J Travel Med. 2023 Dec 21:taad163. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=38127642&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38127642
21. GAO Q, Weng Z, Feng Y, Gong T, et al.
    KPNA2 suppresses porcine epidemic diarrhea virus replication by targeting and
    degrading virus envelope protein through selective autophagy.
    J Virol. 2023;97:e0011523.
    PubMed: https://www.amedeo.com/p2.php?id=38038431&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38038431
22. HARRIS E.
    Using Throat Swabs Improved Sensitivity in Detecting SARS-CoV-2.
    JAMA. 2023 Dec 20. doi: 10.1001/jama.2023.25267.
    PubMed: https://www.amedeo.com/p2.php?id=38117510&s=cov&pm=2
     
    Share: https://m.amedeo.com/38117510
23. HARRIS E.
    Program Offering Free COVID-19 and Flu Services Expands Nationwide.
    JAMA. 2023 Dec 20. doi: 10.1001/jama.2023.25268.
    PubMed: https://www.amedeo.com/p2.php?id=38117506&s=cov&pm=2
     
    Share: https://m.amedeo.com/38117506
24. CHARLIER P.
    Death and end of life in France after COVID-19.
    Lancet. 2023;402:2290.
    PubMed: https://www.amedeo.com/p2.php?id=38103938&s=cov&pm=2
     
    Share: https://m.amedeo.com/38103938
25. HORTON R.
    Offline: Boris Johnson and COVID-19-more light than heat.
    Lancet. 2023;402:2277.
    PubMed: https://www.amedeo.com/p2.php?id=38103935&s=cov&pm=2
     
    Share: https://m.amedeo.com/38103935
26. BLACK CL, Kriss JL, Razzaghi H, Patel SA, et al.
    Influenza, Updated COVID-19, and Respiratory Syncytial Virus Vaccination Coverage
    Among Adults – United States, Fall 2023.
    MMWR Morb Mortal Wkly Rep. 2023;72:1377-1382.
    PubMed: https://www.amedeo.com/p2.php?id=38127675&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38127675
27. HARRINGTON PR, Cong J, Troy SB, Rawson JMO, et al.
    Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in
    Randomized, Double-Blind, Placebo-Controlled Trials – United States and
    International Sites, 2021-2022.
    MMWR Morb Mortal Wkly Rep. 2023;72:1365-1370.
    PubMed: https://www.amedeo.com/p2.php?id=38127674&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38127674
28. RESES HE, Dubendris H, Haas L, Barbre K, et al.
    Coverage with Influenza, Respiratory Syncytial Virus, and Updated COVID-19
    Vaccines Among Nursing Home Residents – National Healthcare Safety Network,
    United States, December 2023.
    MMWR Morb Mortal Wkly Rep. 2023;72:1371-1376.
    PubMed: https://www.amedeo.com/p2.php?id=38127673&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38127673
29. SMITH DJ, Lambrou A, Patel P.
    SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals.
    MMWR Morb Mortal Wkly Rep. 2023;72:1357-1364.
    PubMed: https://www.amedeo.com/p2.php?id=38127665&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38127665
30. Covid Update: ITT Episode 23.
    N Engl J Med. 2023;389:e52.
    PubMed: https://www.amedeo.com/p2.php?id=38118021&s=cov&pm=2
     
    Share: https://m.amedeo.com/38118021
31. BENZLER J.
    Contact-tracing app predicts risk of SARS-CoV-2 transmission.
    Nature. 2023 Dec 21. doi: 10.1038/d41586-023-04063.
    PubMed: https://www.amedeo.com/p2.php?id=38129614&s=cov&pm=2
     
    Share: https://m.amedeo.com/38129614
32. FERRETTI L, Wymant C, Petrie J, Tsallis D, et al.
    Digital measurement of SARS-CoV-2 transmission risk from 7 million contacts.
    Nature. 2023 Dec 20. doi: 10.1038/s41586-023-06952.
    PubMed: https://www.amedeo.com/p2.php?id=38122820&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38122820
33. HALL S.
    Vaccines reduce the risk of long COVID in children.
    Nature. 2023 Dec 20. doi: 10.1038/d41586-023-04032.
    PubMed: https://www.amedeo.com/p2.php?id=38114835&s=cov&pm=2
     
    Share: https://m.amedeo.com/38114835
34. SUTHAR PP, Hughes K, Mafraji M, Akyuz M, et al.
    Case 324.
    Radiology. 2023;309:e222747.
    PubMed: https://www.amedeo.com/p2.php?id=38112552&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38112552
35. ABEGAZ FA, Dos Santos PT, Mogeni OD, Guarnacci T, et al.
    Evaluating Quality Management and Diagnostics Microbiology Performance Within an
    International External Quality Assessment (EQA) Program Serving National One
    Health Sector Reference Laboratories Across Asia: Experience Amid the Coronavirus
    Disease 2019 (COVID-19) Pandemic.
    Clin Infect Dis. 2023;77.
    PubMed: https://www.amedeo.com/p2.php?id=38118017&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38118017
36. KWON SY, Gautam S, Poudel K, Banneheke H, et al.
    Utility and Evaluation of Applied Project Management Processes Within a Large
    Multicountry Health Systems Development Project Conducted During the Coronavirus
    Disease 2019 (COVID-19) Pandemic.
    Clin Infect Dis. 2023;77.
    PubMed: https://www.amedeo.com/p2.php?id=38118010&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38118010
37. MUSTAFA T, Niazi MRK, Lakdawala Z, Mirza S, et al.
    Regional and National Trends in Consumption of Antimicrobials in Pakistan; Pre
    and Post-COVID (2019-2021).
    Clin Infect Dis. 2023;77.
    PubMed: https://www.amedeo.com/p2.php?id=38118009&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38118009
38. LESLIE T, Parry C, Ondoa P, Walsh T, et al.
    The Reality of Antimicrobial Resistance and Antibiotic Usage Data in Asia: The
    CAPTURA Experience.
    Clin Infect Dis. 2023;77.
    PubMed: https://www.amedeo.com/p2.php?id=38118008&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38118008
39. HAYDEN MK, Hanson KE, Englund JA, Lee MJ, et al.
    The Infectious Diseases Society of America Guidelines on the Diagnosis of
    Coronavirus Disease 2019 (COVID-19): Molecular Diagnostic Testing.
    Clin Infect Dis. 2023 Dec 19:ciad646. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=38112284&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38112284
40. SMITH TC.
    Long COVID: Alice Evans, Brucellosis, and Reflections on Infectious Causes of
    Chronic Disease.
    Clin Infect Dis. 2023;77:1644-1647.
    PubMed: https://www.amedeo.com/p2.php?id=37462272&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37462272
41. MONTGOMERY MP, Morris SE, Rolfes MA, Kittikraisak W, et al.
    The role of asymptomatic infections in influenza transmission: what do we really
    know.
    Lancet Infect Dis. 2023 Dec 18:S1473-3099(23)00619.
    PubMed: https://www.amedeo.com/p2.php?id=38128563&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38128563
42. YANG S, Yu Y, Xu Y, Jian F, et al.
    Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure.
    Lancet Infect Dis. 2023 Dec 15:S1473-3099(23)00744.
    PubMed: https://www.amedeo.com/p2.php?id=38109919&s=cov&pm=2
     
    Share: https://m.amedeo.com/38109919
43. GANDHI M.
    Post-viral sequelae of COVID-19 and influenza.
    Lancet Infect Dis. 2023 Dec 14:S1473-3099(23)00762.
    PubMed: https://www.amedeo.com/p2.php?id=38104584&s=cov&pm=2
     
    Share: https://m.amedeo.com/38104584
44. XIE Y, Choi T, Al-Aly Z.
    Long-term outcomes following hospital admission for COVID-19 versus seasonal
    influenza: a cohort study.
    Lancet Infect Dis. 2023 Dec 14:S1473-3099(23)00684.
    PubMed: https://www.amedeo.com/p2.php?id=38104583&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38104583
45. WANG S, Wang Z, Li Y, Tu S, et al.
    Generation of whole-porcine neutralizing antibodies of an alphacoronavirus by
    single B cell antibody technology.
    Antiviral Res. 2023;220:105754.
    PubMed: https://www.amedeo.com/p2.php?id=37967753&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37967753

https://etidioh.wordpress.com/2023/12/25/coronavirus-disease-research-references-by-amedeo-december-25-23/

#betacoronavirus #coronavirus #COVID19 #research #sarbecovirus #sarsCov2

1. PLATT A, Singh M, Stein S, Soherwardi S, et al.
   Replication-Competent Virus Detected in Blood of a Fatal COVID-19 Case.
   Ann Intern Med. 2023 Dec 12. doi: 10.7326/L23-0253.
   PubMed: https://www.amedeo.com/p2.php?id=38079637&s=cov&pm=2
    
   Share: https://m.amedeo.com/38079637
2. ARSHAD Z, Nazareth J, Pareek M.
   Learning to live with covid-19: testing, vaccination, and mask wearing still play
   a key part in managing the pandemic.
   BMJ. 2023;383:p2943.
   PubMed: https://www.amedeo.com/p2.php?id=38097251&s=cov&pm=2
    
   Share: https://m.amedeo.com/38097251
3. WISE J.
   Covid-19: Preliminary figures show 1.2% of people in England had infection at end
   of November.
   BMJ. 2023;383:p2917.
   PubMed: https://www.amedeo.com/p2.php?id=38081655&s=cov&pm=2
    
   Share: https://m.amedeo.com/38081655
4. PETERS MA, Cloete K, Odwe G, Tadele G, et al.
   Embedding implementation research to cross the quality of care chasm during the
   covid-19 pandemic and beyond.
   BMJ. 2023;383:e076331.
   PubMed: https://www.amedeo.com/p2.php?id=38081643&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38081643
5. ZVIEDRITE N, Jahan F, Moreland S, Ahmed F, et al.
   COVID-19-Related School Closures, United States, July 27, 2020-June 30, 2022.
   Emerg Infect Dis. 2023;30.
   PubMed: https://www.amedeo.com/p2.php?id=38086396&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38086396
6. TSOI JYH, Cai J, Situ J, Lam WJ, et al.
   Autoantibodies against angiotensin-converting enzyme 2 (ACE2) after COVID-19
   infection or vaccination.
   J Med Virol. 2023;95:e29313.
   PubMed: https://www.amedeo.com/p2.php?id=38100626&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38100626
7. MEISTER TL, Kirchhoff L, Bruggemann Y, Todt D, et al.
   Stability of pathogens on banknotes and coins: A narrative review.
   J Med Virol. 2023;95:e29312.
   PubMed: https://www.amedeo.com/p2.php?id=38100621&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38100621
8. CHEN Q, Qin S, Zhou HY, Deng YQ, et al.
   Competitive fitness and homologous recombination of SARS-CoV-2 variants of
   concern.
   J Med Virol. 2023;95:e29278.
   PubMed: https://www.amedeo.com/p2.php?id=38088537&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38088537
9. YIN ZJ, Xiao H, McDonald S, Brusic V, et al.
   Dynamically adjustable SVEIR(MH) model of multiwave epidemics: Estimating the
   effects of public health measures against COVID-19.
   J Med Virol. 2023;95:e29301.
   PubMed: https://www.amedeo.com/p2.php?id=38087460&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38087460
10. LI J, Mao H, Song W, Chen Y, et al.
    Low neutralization of SARS-CoV-2 Omicron BA.5.2.48, BF.7.14, XBB.1 subvariants by
    homologous or heterologous booster.
    J Med Virol. 2023;95:e29306.
    PubMed: https://www.amedeo.com/p2.php?id=38084772&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38084772
11. BENNING L, Bartenschlager M, Kim H, Kalble F, et al.
    Live-virus serum neutralization after bivalent SARS-CoV-2 mRNA vaccination in
    hemodialysis patients.
    J Med Virol. 2023;95:e29303.
    PubMed: https://www.amedeo.com/p2.php?id=38082556&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38082556
12. FUKUDA Y, Togashi A, Hirakawa S, Yamamoto M, et al.
    Resurgence of human metapneumovirus infection and influenza after three seasons
    of inactivity in the post-COVID-19 era in Hokkaido, Japan, 2022-2023.
    J Med Virol. 2023;95:e29299.
    PubMed: https://www.amedeo.com/p2.php?id=38081792&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38081792
13. WANG R, Guo J, Lu J, Du P, et al.
    A potential broad-spectrum neutralizing antibody against Betacoronavirus.
    J Med Virol. 2023;95:e29252.
    PubMed: https://www.amedeo.com/p2.php?id=38078658&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38078658
14. XIAO Y, Chang L, Ji H, Sun H, et al.
    Posttranslational modifications of ACE2 protein: Implications for SARS-CoV-2
    infection and beyond.
    J Med Virol. 2023;95:e29304.
    PubMed: https://www.amedeo.com/p2.php?id=38063421&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38063421
15. ANAGNOSTOPOULOS A, Fehr J.
    Rebound and steep increase of international travel after the COVID-19 pandemic:
    where are we going from here?
    J Travel Med. 2023 Dec 14:taad158. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=38097384&s=cov&pm=2
     
    Share: https://m.amedeo.com/38097384
16. FU Z, Xiang Y, Fu Y, Su Z, et al.
    DYRK1A is a multifunctional host factor that regulates coronavirus replication in
    a kinase-independent manner.
    J Virol. 2023 Dec 15:e0123923. doi: 10.1128/jvi.01239.
    PubMed: https://www.amedeo.com/p2.php?id=38099687&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38099687
17. DOMINGO E, Martinez-Gonzalez B, Garcia-Crespo C, Somovilla P, et al.
    Puzzles, challenges, and information reservoir of SARS-CoV-2 quasispecies.
    J Virol. 2023 Nov 21:e0151123. doi: 10.1128/jvi.01511.
    PubMed: https://www.amedeo.com/p2.php?id=38092661&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38092661
18. BOLLAND W, Michel V, Planas D, Hubert M, et al.
    High fusion and cytopathy of SARS-CoV-2 variant B.1.640.1.
    J Virol. 2023 Dec 13:e0135123. doi: 10.1128/jvi.01351.
    PubMed: https://www.amedeo.com/p2.php?id=38088562&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38088562
19. JERONIMO PMC, Aksenen CF, Duarte IO, Lins RD, et al.
    Evolutionary deletions within the SARS-CoV-2 genome as signature trends for virus
    fitness and adaptation.
    J Virol. 2023 Dec 13:e0140423. doi: 10.1128/jvi.01404.
    PubMed: https://www.amedeo.com/p2.php?id=38088350&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38088350
20. GAO W, Wang L, Cui W, Wang H, et al.
    Deubiquitinase USP1 regulates sarbecovirus ORF6 protein function.
    J Virol. 2023 Dec 12:e0143723. doi: 10.1128/jvi.01437.
    PubMed: https://www.amedeo.com/p2.php?id=38084957&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38084957
21. HARRIS E.
    Life Expectancy in US Climbed After Declines Related to COVID-19.
    JAMA. 2023 Dec 13. doi: 10.1001/jama.2023.24683.
    PubMed: https://www.amedeo.com/p2.php?id=38090999&s=cov&pm=2
     
    Share: https://m.amedeo.com/38090999
22. SURAN M.
    Studies Investigate Whether Antivirals Like Paxlovid May Prevent Long COVID.
    JAMA. 2023 Dec 13. doi: 10.1001/jama.2023.24103.
    PubMed: https://www.amedeo.com/p2.php?id=38090997&s=cov&pm=2
     
    Share: https://m.amedeo.com/38090997
23. SPENCER H, Jorgensen E, Seo J, Robinson C, et al.
    Notes from the Field: COVID-19 Pandemic-Related Changes in Blood Lead Screening –
    Chicago, Illinois, 2017-2022.
    MMWR Morb Mortal Wkly Rep. 2023;72:1353-1354.
    PubMed: https://www.amedeo.com/p2.php?id=38096125&s=cov&pm=2
     
    Share: https://m.amedeo.com/38096125
24. MCMAHAN K, Wegmann F, Aid M, Sciacca M, et al.
    Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques.
    Nature. 2023 Dec 14. doi: 10.1038/s41586-023-06951.
    PubMed: https://www.amedeo.com/p2.php?id=38096903&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38096903
25. XING Z, Jeyanathan M.
    A next-generation inhalable dry powder COVID vaccine.
    Nature. 2023 Dec 13. doi: 10.1038/d41586-023-03557.
    PubMed: https://www.amedeo.com/p2.php?id=38093042&s=cov&pm=2
     
    Share: https://m.amedeo.com/38093042
26. What makes people with diabetes more susceptible to serious lung infections?
    Nature. 2023 Dec 13. doi: 10.1038/d41586-023-03647.
    PubMed: https://www.amedeo.com/p2.php?id=38093039&s=cov&pm=2
     
    Share: https://m.amedeo.com/38093039
27. NOBS SP, Kolodziejczyk AA, Adler L, Horesh N, et al.
    Lung dendritic-cell metabolism underlies susceptibility to viral infection in
    diabetes.
    Nature. 2023 Dec 13. doi: 10.1038/s41586-023-06803.
    PubMed: https://www.amedeo.com/p2.php?id=38093014&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38093014
28. YE T, Jiao Z, Li X, He Z, et al.
    Inhaled SARS-CoV-2 vaccine for single-dose dry powder aerosol immunization.
    Nature. 2023 Dec 13. doi: 10.1038/s41586-023-06809.
    PubMed: https://www.amedeo.com/p2.php?id=38093012&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38093012
29. RUGGERI K, Stock F, Haslam SA, Capraro V, et al.
    A synthesis of evidence for policy from behavioural science during COVID-19.
    Nature. 2023 Dec 13. doi: 10.1038/s41586-023-06840.
    PubMed: https://www.amedeo.com/p2.php?id=38093007&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38093007
30. SCIENCE M, Orkin J, Maguire B, Bitnun A, et al.
    Viral dynamics of the SARS-CoV-2 Omicron Variant in Paediatric Patients; A
    prospective cohort study.
    Clin Infect Dis. 2023 Dec 12:ciad740. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=38084906&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38084906
31. RAMAN B, Ramasamy MN.
    Synbiotics in post-acute COVID-19 syndrome-a potential new treatment framework?
    Lancet Infect Dis. 2023 Dec 7:S1473-3099(23)00735.
    PubMed: https://www.amedeo.com/p2.php?id=38071991&s=cov&pm=2
     
    Share: https://m.amedeo.com/38071991
32. LAU RI, Su Q, Lau ISF, Ching JYL, et al.
    A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong
    (RECOVERY): a randomised, double-blind, placebo-controlled trial.
    Lancet Infect Dis. 2023 Dec 7:S1473-3099(23)00685.
    PubMed: https://www.amedeo.com/p2.php?id=38071990&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38071990
33. ZUO F, Cao Y, Sun R, Yisimayi A, et al.
    Neutralisation activity of mucosal IgA against XBB sublineages and BA.2.86.
    Lancet Infect Dis. 2023 Dec 7:S1473-3099(23)00732.
    PubMed: https://www.amedeo.com/p2.php?id=38071989&s=cov&pm=2
     
    Share: https://m.amedeo.com/38071989
34. CARR EJ, Dowgier G, Greenwood D, Herman LS, et al.
    SARS-CoV-2 mucosal neutralising immunity after vaccination.
    Lancet Infect Dis. 2023 Dec 6:S1473-3099(23)00705.
    PubMed: https://www.amedeo.com/p2.php?id=38070528&s=cov&pm=2
     
    Share: https://m.amedeo.com/38070528
35. AKSU M, Kumar P, Guttler T, Taxer W, et al.
    Nanobodies to multiple spike variants and inhalation of nanobody-containing
    aerosols neutralize SARS-CoV-2 in cell culture and hamsters.
    Antiviral Res. 2023 Dec 6:105778. doi: 10.1016/j.antiviral.2023.105778.
    PubMed: https://www.amedeo.com/p2.php?id=38065245&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38065245

https://etidioh.wordpress.com/2023/12/16/coronavirus-disease-research-references-by-amedeo-december-16-23/

#betacoronavirus #coronavirus #covid #COVID19 #health #pandemic #research #sarbecovirus #sarsCov2

1. TRINH IV, Desai SP, Ley SH, Mo Z, et al.
   Prenatal Infection by Respiratory Viruses Is Associated With Immuno-Inflammatory
   Responses in the Fetus.
   Am J Respir Crit Care Med. 2023 Dec 5. doi: 10.1164/rccm.202308-1461.
   PubMed: https://www.amedeo.com/p2.php?id=38051928&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38051928
2. MCKEE M.
   Communicating scientific advice: lessons from the UK covid-19 inquiry.
   BMJ. 2023;383:p2903.
   PubMed: https://www.amedeo.com/p2.php?id=38061791&s=cov&pm=2
    
   Share: https://m.amedeo.com/38061791
3. IACOBUCCI G.
   Covid inquiry: Hancock is grilled on care homes, lockdowns, and testing.
   BMJ. 2023;383:p2868.
   PubMed: https://www.amedeo.com/p2.php?id=38052467&s=cov&pm=2
    
   Share: https://m.amedeo.com/38052467
4. ZANELLA MC, Pianca E, Catho G, Obama B, et al.
   Increased Peripheral Venous Catheter Bloodstream Infections during COVID-19
   Pandemic, Switzerland.
   Emerg Infect Dis. 2023;30.
   PubMed: https://www.amedeo.com/p2.php?id=38063084&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38063084
5. LI J, Liu Y, Wei X, Liu Z, et al.
   Antibody responses to SARS-CoV-2 Omicron infection in patients with hematological
   malignancies: A multicenter, prospective cohort study.
   J Med Virol. 2023;95:e29300.
   PubMed: https://www.amedeo.com/p2.php?id=38063070&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38063070
6. SONG R, Chen X, Li B, Ni J, et al.
   Nasal spray of an IgM-like ACE2 fusion protein HH-120 prevents SARS-CoV-2
   infection: Two investigator-initiated postexposure prophylaxis trials.
   J Med Virol. 2023;95:e29275.
   PubMed: https://www.amedeo.com/p2.php?id=38054556&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38054556
7. HORA S, Pahwa P, Siddiqui H, Saxena A, et al.
   Metabolic alterations unravel the maternofetal immune responses with disease
   severity in pregnant women infected with SARS-CoV-2.
   J Med Virol. 2023;95:e29257.
   PubMed: https://www.amedeo.com/p2.php?id=38054548&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38054548
8. YANG J, Kim HJ, Kim JW, Baek JY, et al.
   Evolution of neutralizing antibodies through vaccination and breakthrough
   infections in the era of COVID-19 endemicity.
   J Med Virol. 2023;95:e29285.
   PubMed: https://www.amedeo.com/p2.php?id=38054545&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38054545
9. GE P, Luo Y, Liu J, Liu J, et al.
   Eliminating COVID-19 as the immediate culprit for igniting pancreatitis.
   J Med Virol. 2023;95:e29272.
   PubMed: https://www.amedeo.com/p2.php?id=38054501&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38054501
10. BAY P, Rodriguez C, Caruso S, Demontant V, et al.
    Omicron induced distinct immune respiratory transcriptomics signatures compared
    to pre-existing variants in critically ill COVID-19 patients.
    J Med Virol. 2023;95:e29268.
    PubMed: https://www.amedeo.com/p2.php?id=38050838&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38050838
11. YU H, Yang L, Han Z, Zhou X, et al.
    SARS-CoV-2 nucleocapsid protein enhances the level of mitochondrial reactive
    oxygen species.
    J Med Virol. 2023;95:e29270.
    PubMed: https://www.amedeo.com/p2.php?id=38047459&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38047459
12. PHAM TX, Huynh TTX, Choi J, Lee J-B, et al.
    SARS-CoV-2 exploits cellular RAD51 to promote viral propagation: implication of
    RAD51 inhibitor as a potential drug candidate against COVID-19.
    J Virol. 2023 Dec 5:e0173723. doi: 10.1128/jvi.01737.
    PubMed: https://www.amedeo.com/p2.php?id=38051260&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38051260
13. RUBIN R.
    Up the Nose and Down the Windpipe May Be the Path to New and Improved COVID-19
    Vaccines.
    JAMA. 2023 Dec 6. doi: 10.1001/jama.2023.0644.
    PubMed: https://www.amedeo.com/p2.php?id=38055302&s=cov&pm=2
     
    Share: https://m.amedeo.com/38055302
14. MATHEW P, Feldmann M.
    Treatment of Adults Hospitalized With COVID-19 Pneumonia.
    JAMA. 2023;330:2122-2123.
    PubMed: https://www.amedeo.com/p2.php?id=38051331&s=cov&pm=2
     
    Share: https://m.amedeo.com/38051331
15. POWDERLY WG, LaVange L, Bozzette SA.
    Treatment of Adults Hospitalized With COVID-19 Pneumonia-Reply.
    JAMA. 2023;330:2123.
    PubMed: https://www.amedeo.com/p2.php?id=38051329&s=cov&pm=2
     
    Share: https://m.amedeo.com/38051329
16. BLAU EF, Balakrishnan MR, Skold H, Santhana Gopala Krishnan RS, et al.
    Progress in Immunization Safety Monitoring – Worldwide, 2020-2022.
    MMWR Morb Mortal Wkly Rep. 2023;72:1321-1326.
    PubMed: https://www.amedeo.com/p2.php?id=38060432&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38060432
17. BENEZECH S, Khoryati L, Cognard J, Netea SA, et al.
    Pre-Covid-19, SARS-CoV-2-Negative Multisystem Inflammatory Syndrome in Children.
    N Engl J Med. 2023;389:2105-2107.
    PubMed: https://www.amedeo.com/p2.php?id=38048195&s=cov&pm=2
     
    Share: https://m.amedeo.com/38048195
18. MULRONEY TE, Poyry T, Yam-Puc JC, Rust M, et al.
    N(1)-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting.
    Nature. 2023 Dec 6. doi: 10.1038/s41586-023-06800.
    PubMed: https://www.amedeo.com/p2.php?id=38057663&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38057663
19. DOLGIN E.
    Self-copying RNA vaccine wins first full approval: what’s next?
    Nature. 2023 Dec 6. doi: 10.1038/d41586-023-03859.
    PubMed: https://www.amedeo.com/p2.php?id=38057473&s=cov&pm=2
     
    Share: https://m.amedeo.com/38057473
20. COHEN J.
    Rare studies expose bats to SARS-CoV-2.
    Science. 2023;382:1098-1099.
    PubMed: https://www.amedeo.com/p2.php?id=38060649&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38060649
21. SALMANTON-GARCIA J, Wipfler P, Leckler J, Naucler P, et al.
    Predicting the next pandemic: VACCELERATE ranking of the World health
    Organization’s Blueprint for action to prevent epidemics.
    Travel Med Infect Dis. 2023 Dec 5:102676. doi: 10.1016/j.tmaid.2023.102676.
    PubMed: https://www.amedeo.com/p2.php?id=38061408&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38061408
22. [Expert consensus on diagnosis and treatment of severe COVID-19 associated with
    pulmonary aspergillus and mucormycosis].
    Zhonghua Jie He He Hu Xi Za Zhi. 2023;47:10-23.
    PubMed: https://www.amedeo.com/p2.php?id=38062689&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38062689
23. WANG SY, Wang YM, Liu M, Zhao L, et al.
    [Migratory pulmonary ground glass opacities caused by SARS-CoV-2 infection in a
    patient on B-cell depletion therapy].
    Zhonghua Jie He He Hu Xi Za Zhi. 2023;46:1233-1239.
    PubMed: https://www.amedeo.com/p2.php?id=38044051&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38044051
24. [Expert consensus on the management of interstitial lung disease during the
    COVID-19 epidemic].
    Zhonghua Jie He He Hu Xi Za Zhi. 2023;46:1204-1218.
    PubMed: https://www.amedeo.com/p2.php?id=38044048&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38044048
25. RYBAK A, Assad Z, Levy C, Bonarcorsi S, et al.
    Age-specific resurgence in invasive pneumococcal disease incidence in the
    COVID-19 pandemic era and its association with respiratory virus and pneumococcal
    carriage dynamics: a time series analysis.
    Clin Infect Dis. 2023 Dec 6:ciad746. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=38059538&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38059538
26. MAKAM AN.
    Unlinking time zero from test-negative controls exaggerates risk from COVID-19.
    Clin Infect Dis. 2023 Dec 6:ciad731. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=38059535&s=cov&pm=2
     
    Share: https://m.amedeo.com/38059535
27. KOW CS, Ramachandram DS, Hasan SS, Thiruchelvam K, et al.
    COVID-19 Vaccination: Safeguarding Against Post-COVID Cardiovascular
    Complications.
    Clin Infect Dis. 2023 Dec 6:ciad732. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=38059531&s=cov&pm=2
     
    Share: https://m.amedeo.com/38059531
28. LIM JT, En WL, Tay AT, Pang D, et al.
    Unlinking time zero from test-negative date does not influence risk estimates of
    long-term cardiovascular complications due to COVID-19.
    Clin Infect Dis. 2023 Dec 6:ciad742. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=38059493&s=cov&pm=2
     
    Share: https://m.amedeo.com/38059493
29. LAVOIE T, Appaneal HJ, LaPlante KL.
    Advancements in Novel Live Biotherapeutic Products for Clostridioides difficile
    Infection Prevention.
    Clin Infect Dis. 2023;77.
    PubMed: https://www.amedeo.com/p2.php?id=38051964&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38051964
30. LEWIS NM, Zhu Y, Peltan ID, Gaglani M, et al.
    Vaccine Effectiveness Against Influenza A-Associated Hospitalization, Organ
    Failure, and Death: United States, 2022-2023.
    Clin Infect Dis. 2023 Dec 5:ciad677. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=38051664&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38051664
31. HOFFMANN CJ, Shearer K, Kekana B, Kerrigan D, et al.
    Reducing HIV-associated post-hospital mortality through home-based care in South
    Africa: a randomized controlled trial.
    Clin Infect Dis. 2023 Dec 5:ciad727. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=38051643&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38051643
32. WANGEN C, Raithel A, Tillmanns J, Gege C, et al.
    Validation of nuclear receptor RORgamma isoform 1 as a novel host-directed antiviral
    target based on the modulation of cholesterol levels.
    Antiviral Res. 2023 Dec 4:105769. doi: 10.1016/j.antiviral.2023.105769.
    PubMed: https://www.amedeo.com/p2.php?id=38056603&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38056603
33. ZUR M, Peselev T, Yanko S, Rotshild V, et al.
    Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients:
    Systematic review and network meta-analysis.
    Antiviral Res. 2023 Dec 4:105768. doi: 10.1016/j.antiviral.2023.105768.
    PubMed: https://www.amedeo.com/p2.php?id=38056602&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38056602
34. GALLUCCI L, Bazire J, Davidson AD, Shytaj IL, et al.
    Broad-spectrum antiviral activity of two structurally analogous CYP3A inhibitors
    against pathogenic human coronaviruses in vitro.
    Antiviral Res. 2023;221:105766.
    PubMed: https://www.amedeo.com/p2.php?id=38042417&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38042417

https://etidioh.wordpress.com/2023/12/09/coronavirus-disease-research-references-by-amedeo-december-9-23/

#betacoronavirus #coronavirus #COVID19 #research #sarbecovirus #sarsCov2

1. LOOI MK.
   “We weren’t that great at treating flu-it should not be our model for covid”:
   America’s covid-19 tsar speaks.
   BMJ. 2023;383:p2743.
   PubMed: https://www.amedeo.com/p2.php?id=38030216&s=cov&pm=2
    
   Share: https://m.amedeo.com/38030216
2. DYER O.
   Pfizer sues Poland over unclaimed covid vaccines.
   BMJ. 2023;383:2810.
   PubMed: https://www.amedeo.com/p2.php?id=38016715&s=cov&pm=2
    
   Share: https://m.amedeo.com/38016715
3. LOOI MK.
   China: Rising cases of respiratory disease and pneumonia spark WHO concern.
   BMJ. 2023;383:2770.
   PubMed: https://www.amedeo.com/p2.php?id=37996101&s=cov&pm=2
    
   Share: https://m.amedeo.com/37996101
4. RIMMER A.
   Clinicians with long covid must get financial support, say unions.
   BMJ. 2023;383:2723.
   PubMed: https://www.amedeo.com/p2.php?id=37977571&s=cov&pm=2
    
   Share: https://m.amedeo.com/37977571
5. HEANEY CD, Hempel H, DeRosa KL, Pinto LA, et al.
   Clinical Assessment of SARS-CoV-2 Antibodies in Oral Fluids Following Infection
   and Vaccination.
   Clin Chem. 2023 Dec 1:hvad169. doi: 10.1093.
   PubMed: https://www.amedeo.com/p2.php?id=38039096&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38039096
6. CHEUNG YYH, Lau EHY, Yin G, Lin Y, et al.
   Effectiveness of Vaccines and Antiviral Drugs in Preventing Severe and Fatal
   COVID-19, Hong Kong.
   Emerg Infect Dis. 2023;30.
   PubMed: https://www.amedeo.com/p2.php?id=38040664&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38040664
7. HUANG PY, Lai CC, Hsu CK.
   Assessing risk factors for COVID-19 pneumonia in Chinese patients with
   pre-existing interstitial lung disease.
   J Med Virol. 2023;95:e29281.
   PubMed: https://www.amedeo.com/p2.php?id=38038270&s=cov&pm=2
    
   Share: https://m.amedeo.com/38038270
8. WU JY, Liu MY, Hung KC, Hsu WH, et al.
   Nutritional deficiency anemia and post-acute sequelae in patients with severe
   acute respiratory syndrome coronavirus 2 infection: A six-month retrospective
   cohort analysis of 30 892 patients.
   J Med Virol. 2023;95:e29246.
   PubMed: https://www.amedeo.com/p2.php?id=38010833&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38010833
9. KANG SW, Kim JW, Kim JY, Lim SY, et al.
   Virological characteristics and the rapid antigen test as deisolation criteria in
   immunocompromised patients with COVID-19: A prospective cohort study.
   J Med Virol. 2023;95:e29228.
   PubMed: https://www.amedeo.com/p2.php?id=38009999&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/38009999
10. LI Z, Xiong Y, Long J, Li T, et al.
    Resurgence of influenza during COVID-19 in Chongqing, China: A retrospective
    analysis.
    J Med Virol. 2023;95:e29249.
    PubMed: https://www.amedeo.com/p2.php?id=38009822&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38009822
11. CHENANE HR, Lingas G, Menidjel R, Laouenan C, et al.
    High sera levels of SARS-CoV-2 N antigen are associated with death in
    hospitalized COVID-19 patients.
    J Med Virol. 2023;95:e29247.
    PubMed: https://www.amedeo.com/p2.php?id=38009713&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38009713
12. WANG Z, Zhao C, Li C, Liu S, et al.
    Molecular PET/CT mapping of rhACE2 distribution and quantification in organs to
    aid in SARS-CoV-2 targeted therapy.
    J Med Virol. 2023;95:e29221.
    PubMed: https://www.amedeo.com/p2.php?id=38009705&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38009705
13. HU GM, Tai YC, Chen CM.
    Unraveling the evolutionary patterns and phylogenomics of coronaviruses: A
    consensus network approach.
    J Med Virol. 2023;95:e29233.
    PubMed: https://www.amedeo.com/p2.php?id=38009694&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38009694
14. MAO R, Fan Z, He M, Li J, et al.
    Acne and COVID-19 susceptibility, hospitalization, and severity: A genetic
    correlation study.
    J Med Virol. 2023;95:e29265.
    PubMed: https://www.amedeo.com/p2.php?id=38009619&s=cov&pm=2
     
    Share: https://m.amedeo.com/38009619
15. KONDO Y, Kawamura Y, Hattori F, Nakai H, et al.
    Serological analysis of severe acute respiratory syndrome coronavirus 2 infection
    in children with Kawasaki disease.
    J Med Virol. 2023;95:e29274.
    PubMed: https://www.amedeo.com/p2.php?id=38009251&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38009251
16. BOYD S, Matsee W, Pisutsan P, Kamolrattanakul S, et al.
    Incidence and Influencing Factors of Psychological Problems among International
    Travelers During Quarantine.
    J Travel Med. 2023 Nov 25:taad151. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=38006361&s=cov&pm=2
     
    Share: https://m.amedeo.com/38006361
17. ZAYOU L, Prakash S, Dhanushkodi NR, Quadiri A, et al.
    A multi-epitope/CXCL11 prime/pull coronavirus mucosal vaccine boosts the
    frequency and the function of lung-resident memory CD4(+) and CD8(+) T cells and
    enhanced protection against COVID-19-like symptoms and death caused by SARS-CoV-2
    infection.
    J Virol. 2023 Dec 1:e0109623. doi: 10.1128/jvi.01096.
    PubMed: https://www.amedeo.com/p2.php?id=38038432&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38038432
18. SO RTY, Chu DKW, Hui KPY, Mok CKP, et al.
    Amino acid substitution L232F in non-structural protein 6 identified as a
    possible human-adaptive mutation in clade B MERS coronaviruses.
    J Virol. 2023 Dec 1:e0136923. doi: 10.1128/jvi.01369.
    PubMed: https://www.amedeo.com/p2.php?id=38038429&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38038429
19. LI K, Huntwork RHC, Horn GQ, Abraha M, et al.
    Cryptic-site-specific antibodies to the SARS-CoV-2 receptor binding domain can
    retain functional binding affinity to spike variants.
    J Virol. 2023 Nov 29:e0107023. doi: 10.1128/jvi.01070.
    PubMed: https://www.amedeo.com/p2.php?id=38019013&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38019013
20. YANG S, Huang X, Li S, Wang C, et al.
    Linoleic acid: a natural feed compound against porcine epidemic diarrhea disease.
    J Virol. 2023 Nov 27:e0170023. doi: 10.1128/jvi.01700.
    PubMed: https://www.amedeo.com/p2.php?id=38009930&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38009930
21. WANG Z, He W, Li C, Chen Y, et al.
    The role of lysosomes as intermediates in betacoronavirus PHEV egress from nerve
    cells.
    J Virol. 2023 Nov 27:e0133823. doi: 10.1128/jvi.01338.
    PubMed: https://www.amedeo.com/p2.php?id=38009916&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38009916
22. NARAYANAN KK, Amaya M, Tsang N, Yin R, et al.
    Sequence basis for selectivity of ephrin-B2 ligand for Eph receptors and
    pathogenic henipavirus G glycoproteins.
    J Virol. 2023;97:e0062123.
    PubMed: https://www.amedeo.com/p2.php?id=37931130&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37931130
23. SCHMIDT M, Hajage D, Lebreton G, Dres M, et al.
    Prone Positioning During Extracorporeal Membrane Oxygenation in Patients With
    Severe ARDS: The PRONECMO Randomized Clinical Trial.
    JAMA. 2023 Dec 1. doi: 10.1001/jama.2023.24491.
    PubMed: https://www.amedeo.com/p2.php?id=38038395&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38038395
24. EASTMAN Q.
    Study Shows Businesses Selling Unapproved Stem Cell Treatments Have Turned to
    Long COVID.
    JAMA. 2023 Nov 29. doi: 10.1001/jama.2023.23897.
    PubMed: https://www.amedeo.com/p2.php?id=38019493&s=cov&pm=2
     
    Share: https://m.amedeo.com/38019493
25. BERGMAN C.
    Treatment of SARS-CoV-2 Infection in US Nursing Homes.
    JAMA. 2023;330:2021-2022.
    PubMed: https://www.amedeo.com/p2.php?id=38015226&s=cov&pm=2
     
    Share: https://m.amedeo.com/38015226
26. MCGARRY BE, Sommers BD, Barnett ML.
    Treatment of SARS-CoV-2 Infection in US Nursing Homes-Reply.
    JAMA. 2023;330:2022.
    PubMed: https://www.amedeo.com/p2.php?id=38015222&s=cov&pm=2
     
    Share: https://m.amedeo.com/38015222
27. HARRIS E.
    Audit Finds US National Stockpile “Was Not Equipped” for the Pandemic.
    JAMA. 2023;330:1828.
    PubMed: https://www.amedeo.com/p2.php?id=37910119&s=cov&pm=2
     
    Share: https://m.amedeo.com/37910119
28. VALENCIA D, Yu AT, Wheeler A, Hopkins L, et al.
    Notes from the Field: The National Wastewater Surveillance System’s Centers of
    Excellence Contributions to Public Health Action During the Respiratory Virus
    Season – Four U.S. Jurisdictions, 2022-23.
    MMWR Morb Mortal Wkly Rep. 2023;72:1309-1312.
    PubMed: https://www.amedeo.com/p2.php?id=38032883&s=cov&pm=2
     
    Share: https://m.amedeo.com/38032883
29. TANNIS A, Englund JA, Perez A, Harker EJ, et al.
    SARS-CoV-2 Epidemiology and COVID-19 mRNA Vaccine Effectiveness Among Infants and
    Children Aged 6 Months-4 Years – New Vaccine Surveillance Network, United States,
    July 2022-September 2023.
    MMWR Morb Mortal Wkly Rep. 2023;72:1300-1306.
    PubMed: https://www.amedeo.com/p2.php?id=38032834&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38032834
30. CALLAWAY E.
    These volunteers want to be infected with disease to aid research – will their
    altruism help?
    Nature. 2023 Nov 28. doi: 10.1038/d41586-023-03583.
    PubMed: https://www.amedeo.com/p2.php?id=38017067&s=cov&pm=2
     
    Share: https://m.amedeo.com/38017067
31. CONROY G.
    What’s behind China’s mysterious wave of childhood pneumonia?
    Nature. 2023 Nov 27. doi: 10.1038/d41586-023-03732.
    PubMed: https://www.amedeo.com/p2.php?id=38012356&s=cov&pm=2
     
    Share: https://m.amedeo.com/38012356
32. JAIN V.
    Infection Control and Prevention During the COVID-19 Pandemic.
    Clin Infect Dis. 2023 Nov 30:ciad611. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=38031388&s=cov&pm=2
     
    Share: https://m.amedeo.com/38031388
33. USDAN L, Patel S, Rodriguez H, Xu X, et al.
    A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in >/=12-Year-Olds.
    Clin Infect Dis. 2023 Nov 28:ciad718. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=38016021&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38016021
34. LEE N, Nguyen L, Austin PC, Brown KA, et al.
    Protection conferred by COVID-19 vaccination, prior SARS-CoV-2 infection, or
    hybrid immunity against Omicron-associated severe outcomes among
    community-dwelling adults.
    Clin Infect Dis. 2023 Nov 24:ciad716. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=38001037&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38001037
35. GRANEROD J, Huang Y, Davies NWS, Sequeira PC, et al.
    Global Landscape of Encephalitis: Key Priorities to Reduce Future Disease Burden.
    Clin Infect Dis. 2023;77:1552-1560.
    PubMed: https://www.amedeo.com/p2.php?id=37436770&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37436770
36. DE LUSIGNAN S, Hobbs FR, Sheikh A.
    Lessons from the English primary care sentinel network’s response to the COVID-19
    pandemic.
    Lancet Infect Dis. 2023 Nov 28:S1473-3099(23)00736.
    PubMed: https://www.amedeo.com/p2.php?id=38040007&s=cov&pm=2
     
    Share: https://m.amedeo.com/38040007
37. GOTTLIEB RL, Paredes R.
    Oral and intravenous 1′-cyano-substituted adenosine-like antivirals for early
    COVID-19.
    Lancet Infect Dis. 2023 Nov 22:S1473-3099(23)00633.
    PubMed: https://www.amedeo.com/p2.php?id=38006893&s=cov&pm=2
     
    Share: https://m.amedeo.com/38006893
38. FAN X, Dai X, Ling Y, Wu L, et al.
    Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a
    multicentre, double-blind, phase 3, randomised controlled study.
    Lancet Infect Dis. 2023 Nov 22:S1473-3099(23)00577.
    PubMed: https://www.amedeo.com/p2.php?id=38006892&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38006892
39. BURKI T.
    UK Covid-19 Inquiry.
    Lancet Infect Dis. 2023;23:e516-e517.
    PubMed: https://www.amedeo.com/p2.php?id=38006889&s=cov&pm=2
     
    Share: https://m.amedeo.com/38006889
40. BAGCCHI S.
    Boost for COVID-19 testing in the USA.
    Lancet Infect Dis. 2023;23:e514.
    PubMed: https://www.amedeo.com/p2.php?id=38006887&s=cov&pm=2
     
    Share: https://m.amedeo.com/38006887
41. WANG S, Cui H, Zhang C, Li W, et al.
    Oral delivery of a chitosan adjuvanted COVID-19 vaccine provides long-lasting and
    broad-spectrum protection against SARS-CoV-2 variants of concern in golden
    hamsters.
    Antiviral Res. 2023 Nov 28:105765. doi: 10.1016/j.antiviral.2023.105765.
    PubMed: https://www.amedeo.com/p2.php?id=38036065&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38036065
42. FORRESTALL K, Pringle ES, Sands D, Duguay BA, et al.
    A phenothiazine urea derivative broadly inhibits coronavirus replication via
    viral protease inhibition.
    Antiviral Res. 2023;220:105758.
    PubMed: https://www.amedeo.com/p2.php?id=38008194&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38008194
43. SUBRAMANI C, Sharma G, Chaira T, Barman TK, et al.
    High content screening strategies for large-scale compound libraries with a focus
    on high-containment viruses.
    Antiviral Res. 2023 Nov 24:105764. doi: 10.1016/j.antiviral.2023.105764.
    PubMed: https://www.amedeo.com/p2.php?id=38008193&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/38008193

https://etidioh.wordpress.com/2023/12/02/coronavirus-disease-research-references-by-amedeo-december-2nd-23/

#betacoronavirus #coronavirus #covid #COVID19 #microglia #mitochondria #neuroinflammation #research #sarbecovirus #sarsCov2

1. CHOW JWY, Al-Bassam W, Yanase F, O’Brien Z, et al.
   P0.1 During Pressure Support Ventilation.
   Am J Respir Crit Care Med. 2023 Nov 22. doi: 10.1164/rccm.202307-1314.
   PubMed: https://www.amedeo.com/p2.php?id=37991405&s=cov&pm=2
    
   Share: https://m.amedeo.com/37991405
2. FEYS S, Hoenigl M, Gangneux JP MD, PhD, FECMM, Verweij PE, et al.
   Fungal Fog in Viral Storms: Necessity for Rigor in Aspergillosis Diagnosis and Research.
   Am J Respir Crit Care Med. 2023 Nov 16. doi: 10.1164/rccm.202310-1815.
   PubMed: https://www.amedeo.com/p2.php?id=37972350&s=cov&pm=2
    
   Share: https://m.amedeo.com/37972350
3. LUNDBERG-MORRIS L, Leach S, Xu Y, Martikainen J, et al.
   Covid-19 vaccine effectiveness against post-covid-19 condition among 589 722 individuals in Sweden: population based cohort study.
   BMJ. 2023;383:e076990.
   PubMed: https://www.amedeo.com/p2.php?id=37993131&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37993131
4. BUCK AM, Deitchman AN, Takahashi S, Lu S, et al.
   The breadth of the neutralizing antibody response to original SARS-CoV-2 infection is linked to the presence of Long COVID symptoms.
   J Med Virol. 2023;95:e29216.
   PubMed: https://www.amedeo.com/p2.php?id=37988251&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37988251
5. LOW K, Moller R, Stegmann C, Becker M, et al.
   Luminescent reporter cells enable the identification of broad-spectrum antivirals against emerging viruses.
   J Med Virol. 2023;95:e29211.
   PubMed: https://www.amedeo.com/p2.php?id=37975336&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37975336
6. ABDOLAHI T, Maamouri G, Behmadi M, Mirzaeian S, et al.
   Investigating the impact of Sinopharm COVID-19 vaccination on antibody response in pregnant women and their newborns.
   J Med Virol. 2023;95:e29231.
   PubMed: https://www.amedeo.com/p2.php?id=37971780&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37971780
7. RIVAS G, Labiod N, Luczkowiak J, Lasala F, et al.
   Superior neutralizing response after first versus second SARS-CoV-2 infection in fully vaccinated individuals.
   J Med Virol. 2023;95:e29225.
   PubMed: https://www.amedeo.com/p2.php?id=37971751&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37971751
8. BRAGAZZI CUNHA J, Leix K, Sherman EJ, Mirabelli C, et al.
   Type I interferon signaling induces a delayed antiproliferative response in respiratory epithelial cells during SARS-CoV-2 infection.
   J Virol. 2023 Nov 17:e0127623. doi: 10.1128/jvi.01276.
   PubMed: https://www.amedeo.com/p2.php?id=37975674&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37975674
9. NIU X, Liu M, Yang S, Xu J, et al.
   A recombination-resistant genome for live attenuated and stable PEDV vaccines by engineering the transcriptional regulatory sequences.
   J Virol. 2023 Nov 16:e0119323. doi: 10.1128/jvi.01193.
   PubMed: https://www.amedeo.com/p2.php?id=37971221&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37971221
10. HARRIS E.
    COVID Moonshot Drove Discovery of Potential COVID-19 Antivirals.
    JAMA. 2023 Nov 22. doi: 10.1001/jama.2023.22934.
    PubMed: https://www.amedeo.com/p2.php?id=37991808&s=cov&pm=2
     
    Share: https://m.amedeo.com/37991808
11. HARRIS E.
    Smell, Taste Issues After Mild COVID-19 Resolve Over 3 Years.
    JAMA. 2023 Nov 22. doi: 10.1001/jama.2023.22930.
    PubMed: https://www.amedeo.com/p2.php?id=37991803&s=cov&pm=2
     
    Share: https://m.amedeo.com/37991803
12. STEWART TG, Rebolledo PA, Mourad A, Lindsell CJ, et al.
    Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial.
    JAMA. 2023 Nov 17:e2323363. doi: 10.1001/jama.2023.23363.
    PubMed: https://www.amedeo.com/p2.php?id=37976072&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37976072
13. HARRIS E.
    Long COVID Linked With Viral Persistence, Serotonin Decline.
    JAMA. 2023;330:1827.
    PubMed: https://www.amedeo.com/p2.php?id=37910132&s=cov&pm=2
     
    Share: https://m.amedeo.com/37910132
14. ZIAUDDEEN N, Pantelic M, O’Hara ME, Hastie C, et al.
    Impact of long COVID-19 on work: a co-produced survey.
    Lancet. 2023;402 Suppl 1:S98.
    PubMed: https://www.amedeo.com/p2.php?id=37997145&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37997145
15. VAN YPEREN J, Campillo-Funollet E, Memon A, Allman P, et al.
    The Sussex COVID-19 Modelling Cell: the methods and successes of a collaboration between public health teams in local authorities, NHS hospital trusts, NHS commissioners, and universities.
    Lancet. 2023;402 Suppl 1:S94.
    PubMed: https://www.amedeo.com/p2.php?id=37997141&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37997141
16. WRENN K, Blomquist PB, Inzoungou-Massanga C, Olufon O, et al.
    Surge of lower respiratory tract group A streptococcal infections in England in winter 2022: epidemiology and clinical profile.
    Lancet. 2023;402 Suppl 1:S93.
    PubMed: https://www.amedeo.com/p2.php?id=37997140&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37997140
17. RAMASAWMY M, Khan N, Sunkersing D, Banerjee A, et al.
    Understanding ethnic inequalities in the design and implementation of digital health interventions for cardiometabolic disease: a qualitative study.
    Lancet. 2023;402 Suppl 1:S78.
    PubMed: https://www.amedeo.com/p2.php?id=37997123&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37997123
18. Nowcasting waiting lists for elective procedures and surgery in England: a modelling study.
    Lancet. 2023;402 Suppl 1:S74.
    PubMed: https://www.amedeo.com/p2.php?id=37997119&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37997119
19. MURPHY MH, O’Kane SM, Carlin A, Lahart IM, et al.
    A peer-led walking intervention for adolescent girls (the WISH study): a cluster-randomised controlled trial.
    Lancet. 2023;402 Suppl 1:S72.
    PubMed: https://www.amedeo.com/p2.php?id=37997117&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37997117
20. MORENO-AGOSTINO D, Das-Munshi J, Ploubidis GB.
    Differences in the impact of the COVID-19 pandemic in the long-term trajectories of life satisfaction by sex in the UK: a prospective cohort study.
    Lancet. 2023;402 Suppl 1:S71.
    PubMed: https://www.amedeo.com/p2.php?id=37997116&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37997116
21. MARTIN A, Jamieson S.
    Exploring the experiences of junior doctors who were shielding during the COVID-19 pandemic: a qualitative study of semi-structured interviews.
    Lancet. 2023;402 Suppl 1:S68.
    PubMed: https://www.amedeo.com/p2.php?id=37997112&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37997112
22. KROMYDAS T, Demou E, Leyland AH, Katikireddi SV, et al.
    Effect of trade unions on the mental health of UK workers before and during the COVID-19 pandemic: a longitudinal analysis using Understanding Society data.
    Lancet. 2023;402 Suppl 1:S62.
    PubMed: https://www.amedeo.com/p2.php?id=37997106&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37997106
23. KHAN Y, Verhaeghe N, Devleesschauwer B, Cavillot L, et al.
    Impact of the COVID-19 pandemic on delayed care of cardiovascular diseases in Europe: a systematic review.
    Lancet. 2023;402 Suppl 1:S61.
    PubMed: https://www.amedeo.com/p2.php?id=37997105&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37997105
24. KALBUS A, Cornelsen L, Ballatore A, Cummins S, et al.
    Changes in food and drink purchasing behaviour in England during the first 3 months of the COVID-19 pandemic: an interrupted time-series analysis.
    Lancet. 2023;402 Suppl 1:S60.
    PubMed: https://www.amedeo.com/p2.php?id=37997104&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37997104
25. HINDOCHA A, Brennan L, Brewster L, Lunn J, et al.
    The wider health and wellbeing needs of those accessing paediatric care in England: engaging with the hidden voices of children and young people.
    Lancet. 2023;402 Suppl 1:S50.
    PubMed: https://www.amedeo.com/p2.php?id=37997093&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37997093
26. HAZIR SG, Ryan C, Moore A, Lewis C, et al.
    The role of the multiple Index of deprivation in predicting mental health outcomes after the COVID-19 pandemic in adolescents: a cross-sectional study.
    Lancet. 2023;402 Suppl 1:S47.
    PubMed: https://www.amedeo.com/p2.php?id=37997089&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37997089
27. DU Z, Wang L, Bai Y, Pei Y, et al.
    Mitigation of respiratory syncytial virus epidemics by RSVpreF vaccines after the COVID-19 pandemic in the UK: a modelling study.
    Lancet. 2023;402 Suppl 1:S39.
    PubMed: https://www.amedeo.com/p2.php?id=37997080&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37997080
28. DOBBIN J, Soares CA, Burns F, Miall N, et al.
    Medical consequences of “contingency accommodation” for people seeking asylum: thematic analysis of a survey from professionals working in contingency accommodation.
    Lancet. 2023;402 Suppl 1:S38.
    PubMed: https://www.amedeo.com/p2.php?id=37997079&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37997079
29. ARNOTT J, Troya MI, Joyce M, Khashan A, et al.
    Untangling the association between COVID-19 health literacy, trust in the pandemic response, and mental distress, during the COVID-19 pandemic in Ireland: a repeated cross-sectional study.
    Lancet. 2023;402 Suppl 1:S23.
    PubMed: https://www.amedeo.com/p2.php?id=37997063&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37997063
30. ACHARYA A, Darzi A, Judah G.
    An SMS and animated video intervention to increase uptake of breast cancer screening: a randomised controlled trial.
    Lancet. 2023;402 Suppl 1:S17.
    PubMed: https://www.amedeo.com/p2.php?id=37997056&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37997056
31. CEJTIN HE, Warren EF, Guidry T, Boss K, et al.
    Notes from the Field: Diagnosis of Congenital Syphilis and Syphilis Among Females of Reproductive Age Before and During the COVID-19 Pandemic – Chicago, 2015-2022.
    MMWR Morb Mortal Wkly Rep. 2023;72:1288-1289.
    PubMed: https://www.amedeo.com/p2.php?id=37991996&s=cov&pm=2
     
    Share: https://m.amedeo.com/37991996
32. MINTA AA, Ferrari M, Antoni S, Portnoy A, et al.
    Progress Toward Measles Elimination – Worldwide, 2000-2022.
    MMWR Morb Mortal Wkly Rep. 2023;72:1262-1268.
    PubMed: https://www.amedeo.com/p2.php?id=37971951&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37971951
33. SANDERSON K.
    ‘Politicians don’t understand science’: advisers give evidence at UK COVID inquiry.
    Nature. 2023 Nov 23. doi: 10.1038/d41586-023-03706.
    PubMed: https://www.amedeo.com/p2.php?id=37996747&s=cov&pm=2
     
    Share: https://m.amedeo.com/37996747
34. YISIMAYI A, Song W, Wang J, Jian F, et al.
    Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting.
    Nature. 2023 Nov 22. doi: 10.1038/s41586-023-06753.
    PubMed: https://www.amedeo.com/p2.php?id=37993710&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37993710
35. The highly mutated SARS-CoV-2 variant BA.2.86 is still neutralized by antibodies in the blood.
    Nature. 2023 Nov 21. doi: 10.1038/d41586-023-03376.
    PubMed: https://www.amedeo.com/p2.php?id=37990092&s=cov&pm=2
     
    Share: https://m.amedeo.com/37990092
36. OFFORD C.
    Novel coronavirus blamed for Cyprus cat deaths.
    Science. 2023;382:869.
    PubMed: https://www.amedeo.com/p2.php?id=37995239&s=cov&pm=2
     
    Share: https://m.amedeo.com/37995239
37. FUENTES A.
    Humans are biocultural, science should be too.
    Science. 2023;382:eadl1517.
    PubMed: https://www.amedeo.com/p2.php?id=37972180&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37972180
38. NABAVI E, Razavi S.
    The responsibility turn The Politics of Modelling: Numbers Between Science and Policy Andrea Saltelli and Monica Di Fiore, Eds. Oxford University Press, 2023.
    272 pp.
    Science. 2023;382:775.
    PubMed: https://www.amedeo.com/p2.php?id=37972171&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37972171
39. THORP HH.
    Correction is courageous.
    Science. 2023;382:743.
    PubMed: https://www.amedeo.com/p2.php?id=37943961&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37943961
40. HERBERT C, Manabe YC, Filippaios A, Lin H, et al.
    Differential Viral Dynamics by Sex and Body Mass Index During Acute SARS-CoV-2 Infection: Results from a Longitudinal Cohort Study.
    Clin Infect Dis. 2023 Nov 16:ciad701. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=37972270&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37972270
41. STANKOV MV, Hoffmann M, Gutierrez Jauregui R, Cossmann A, et al.
    Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination.
    Lancet Infect Dis. 2023 Nov 20:S1473-3099(23)00690.
    PubMed: https://www.amedeo.com/p2.php?id=37995739&s=cov&pm=2
     
    Share: https://m.amedeo.com/37995739
42. GOMEZ-CARBALLA A, Albericio G, Montoto-Louzao J, Perez P, et al.
    Lung transcriptomics of K18-hACE2 mice highlights mechanisms and genes involved in the MVA-S vaccine-mediated immune response and protection against SARS-CoV-2 infection.
    Antiviral Res. 2023 Nov 20:105760. doi: 10.1016/j.antiviral.2023.105760.
    PubMed: https://www.amedeo.com/p2.php?id=37992765&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37992765
43. WU CY, Tseng YC, Kao SE, Wu LY, et al.
    Monoglycosylated SARS-CoV-2 receptor binding domain fused with
    HA(stem)-scaffolded protein vaccine confers broad protective immunity against SARS-CoV-2 and influenza viruses.
    Antiviral Res. 2023 Nov 18:105759. doi: 10.1016/j.antiviral.2023.105759.
    PubMed: https://www.amedeo.com/p2.php?id=37984568&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37984568
44. ZHANG QY, Zhang HQ, Zhang YN, Zhang ZR, et al.
    Newcastle Disease Virus (NDV)-based vaccine candidate against SARS-CoV-2 Omicron by intranasal immunization.
    Antiviral Res. 2023 Nov 18:105757. doi: 10.1016/j.antiviral.2023.105757.
    PubMed: https://www.amedeo.com/p2.php?id=37984567&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37984567
45. CHUANG YT, Lin YL, Lin JY.
    Licochalcone A regulates viral IRES activity to inhibit enterovirus replication.
    Antiviral Res. 2023 Nov 18:105755. doi: 10.1016/j.antiviral.2023.105755.
    PubMed: https://www.amedeo.com/p2.php?id=37984566&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37984566

*** End ***

https://etidioh.wordpress.com/2023/11/25/coronavirus-disease-research-references-by-amedeo-november-25-23/

#betacoronavirus #coronavirus #COVID19 #research #sarbecovirus #sarsCov2

1. MICHELS EHA, Appelman B, de Brabander J, van Amstel RBE, et al.
   Host Response Changes and Their Association with Mortality in COVID-19 Patients
   with Lymphopenia.
   Am J Respir Crit Care Med. 2023 Nov 10. doi: 10.1164/rccm.202305-0890.
   PubMed: https://www.amedeo.com/p2.php?id=37948687&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37948687
2. COHEN MS, Brown ER.
   Rebound of COVID-19 With Nirmatrelvir-Ritonavir Antiviral Therapy.
   Ann Intern Med. 2023 Nov 14. doi: 10.7326/M23-2887.
   PubMed: https://www.amedeo.com/p2.php?id=37956432&s=cov&pm=2
    
   Share: https://m.amedeo.com/37956432
3. EDELSTEIN GE, Boucau J, Uddin R, Marino C, et al.
   SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy : An
   Observational Study.
   Ann Intern Med. 2023 Nov 14. doi: 10.7326/M23-1756.
   PubMed: https://www.amedeo.com/p2.php?id=37956428&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37956428
4. SHIN GY.
   Covid-19: excess death rates and the cost of living crisis.
   BMJ. 2023;383:p2612.
   PubMed: https://www.amedeo.com/p2.php?id=37957011&s=cov&pm=2
    
   Share: https://m.amedeo.com/37957011
5. HAM C.
   What have we learnt from the covid-19 inquiry so far?
   BMJ. 2023;383:p2654.
   PubMed: https://www.amedeo.com/p2.php?id=37957007&s=cov&pm=2
    
   Share: https://m.amedeo.com/37957007
6. ANDREIS TF, Cantarelli VV, da Silva MB, Helfer MS, et al.
   Substantial Diversity in Cocirculating Omicron Lineages in Hospital Setting,
   Porto Alegre, Brazil.
   Emerg Infect Dis. 2023;29.
   PubMed: https://www.amedeo.com/p2.php?id=37966098&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37966098
7. WANG B, Yang W, Tong Y, Sun M, et al.
   Integrative proteomics and metabolomics study reveal enhanced immune responses by
   COVID-19 vaccine booster shot against Omicron SARS-CoV-2 infection.
   J Med Virol. 2023;95:e29219.
   PubMed: https://www.amedeo.com/p2.php?id=37966997&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37966997
8. SPRINGER DN, Reuberger E, Borsodi C, Puchhammer-Stockl E, et al.
   Comparison of anti-nucleocapsid antibody assays for the detection of SARS-CoV-2
   Omicron vaccine breakthroughs after various intervals since the infection.
   J Med Virol. 2023;95:e29229.
   PubMed: https://www.amedeo.com/p2.php?id=37966995&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37966995
9. KIM Y, Kim Y, Lim HJ, Kim DK, et al.
   Integrative single-cell transcriptome analysis provides new insights into
   post-COVID-19 pulmonary fibrosis and potential therapeutic targets.
   J Med Virol. 2023;95:e29201.
   PubMed: https://www.amedeo.com/p2.php?id=37966390&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37966390
10. LIU D, Wang Z, Mao M, Zhang Z, et al.
    Application of whole-genome tiling array at Shanghai port, China: An alternative
    method for SARS-CoV-2 surveillance.
    J Med Virol. 2023;95:e29222.
    PubMed: https://www.amedeo.com/p2.php?id=37964661&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37964661
11. HARRIS E.
    Combined COVID-19, Flu Vaccine Candidate Headed to Phase 3 Trials.
    JAMA. 2023 Nov 15. doi: 10.1001/jama.2023.22353.
    PubMed: https://www.amedeo.com/p2.php?id=37966868&s=cov&pm=2
     
    Share: https://m.amedeo.com/37966868
12. How our memories of COVID-19 are biased – and why it matters.
    Nature. 2023;623:458.
    PubMed: https://www.amedeo.com/p2.php?id=37964065&s=cov&pm=2
     
    Share: https://m.amedeo.com/37964065
13. RAMASAUSKAITE RAMASAUSKAITE D, Grinciute Grinciute D.
    Review of short-term and long-term adverse effects of covid-19 vaccination during
    pregnancy.
    Travel Med Infect Dis. 2023 Nov 9:102667. doi: 10.1016/j.tmaid.2023.102667.
    PubMed: https://www.amedeo.com/p2.php?id=37951411&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37951411
14. BOULWARE DR.
    When Someone Should Do Something About This: How a Cryptococcal Clinical Trialist
    Became Involved With the Coronavirus Disease 2019 Pandemic.
    Clin Infect Dis. 2023 Nov 16:ciad648. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=37968886&s=cov&pm=2
     
    Share: https://m.amedeo.com/37968886
15. SMITH-JEFFCOAT SE, Biddle JE, Talbot HK, Morrisey KG, et al.
    Symptoms, viral loads, and rebound among COVID-19 outpatients treated with
    nirmatrelvir/ritonavir compared to propensity score matched untreated
    individuals.
    Clin Infect Dis. 2023 Nov 14:ciad696. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=37963102&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37963102
16. KANJILAL S.
    Flying Into the Future With Large Language Models.
    Clin Infect Dis. 2023 Nov 14:ciad635. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=37963099&s=cov&pm=2
     
    Share: https://m.amedeo.com/37963099
17. SPINELLI MA, Christopoulos KA, Moreira CV, Jain JP, et al.
    Viral Suppression Trajectories Destabilized After Coronavirus Disease 2019 Among
    US People With Human Immunodeficiency Virus: An Interrupted Time Series Analysis.
    Clin Infect Dis. 2023 Nov 14:ciad657. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=37963086&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37963086
18. MEYEROWITZ EA, Li Y.
    Review: The Landscape of Antiviral Therapy for COVID-19 in the Era of Widespread
    Population Immunity and Omicron-Lineage Viruses.
    Clin Infect Dis. 2023 Nov 9:ciad685. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=37949817&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37949817
19. LASSAUNIERE R, Polacek C, Utko M, Sorensen KM, et al.
    Virus isolation and neutralisation of SARS-CoV-2 variants BA.2.86 and EG.5.1.
    Lancet Infect Dis. 2023 Nov 7:S1473-3099(23)00682.
    PubMed: https://www.amedeo.com/p2.php?id=37949089&s=cov&pm=2
     
    Share: https://m.amedeo.com/37949089
20. SADHU S, Dandotiya J, Dalal R, Khatri R, et al.
    Fangchinoline inhibits SARS-CoV-2 and MERS-CoV entry.
    Antiviral Res. 2023 Nov 8:105743. doi: 10.1016/j.antiviral.2023.105743.
    PubMed: https://www.amedeo.com/p2.php?id=37949319&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37949319
21. HSIEH HC, Chen CC, Chou PH, Liu WC, et al.
    Induction of neutralizing antibodies and mucosal IgA through intranasal
    immunization with the receptor binding domain of SARS-CoV-2 spike protein fused
    with the type IIb E. coli heat-labile enterotoxin A subunit.
    Antiviral Res. 2023 Nov 8:105752. doi: 10.1016/j.antiviral.2023.105752.
    PubMed: https://www.amedeo.com/p2.php?id=37949318&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37949318

https://etidioh.wordpress.com/2023/11/18/coronavirus-disease-research-references-by-amedeo-november-18-23/

#betacoronavirus #coronavirus #COVID19 #research #sarbecovirus #sarsCov2

1. LAL A, Gladwin MT, Gajic O.
   Inhaled NO in COVID-19 ARDS: Yes, or No?
   Am J Respir Crit Care Med. 2023 Nov 7. doi: 10.1164/rccm.202310-1823.
   PubMed: https://www.amedeo.com/p2.php?id=37934465&s=cov&pm=2
    
   Share: https://m.amedeo.com/37934465
2. Update to living WHO guideline on drugs for covid-19.
   BMJ. 2023;383:p2622.
   PubMed: https://www.amedeo.com/p2.php?id=37945036&s=cov&pm=2
    
   Share: https://m.amedeo.com/37945036
3. TAYLOR L.
   Treatment of TB is recovering after covid-19 but well short of 2025 targets, says
   WHO.
   BMJ. 2023;383:p2618.
   PubMed: https://www.amedeo.com/p2.php?id=37940183&s=cov&pm=2
    
   Share: https://m.amedeo.com/37940183
4. LANG K.
   Is convalescent plasma still useful as a covid treatment?
   BMJ. 2023;383:p2185.
   PubMed: https://www.amedeo.com/p2.php?id=37940147&s=cov&pm=2
    
   Share: https://m.amedeo.com/37940147
5. SHEPHERD A.
   Covid NHS memorial is named year’s top statue.
   BMJ. 2023;383:p2594.
   PubMed: https://www.amedeo.com/p2.php?id=37931944&s=cov&pm=2
    
   Share: https://m.amedeo.com/37931944
6. DYER C.
   Covid-19: Whitehall chaos and misplaced confidence undermined UK’s response,
   inquiry hears.
   BMJ. 2023;383:p2576.
   PubMed: https://www.amedeo.com/p2.php?id=37923326&s=cov&pm=2
    
   Share: https://m.amedeo.com/37923326
7. ZHANG YN, Zhu GH, Liu W, Chen XX, et al.
   Discovery of the covalent SARS-CoV-2 M(pro) inhibitors from antiviral herbs via
   integrating target-based high-throughput screening and chemoproteomic approaches.
   J Med Virol. 2023;95:e29208.
   PubMed: https://www.amedeo.com/p2.php?id=37947293&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37947293
8. NGIAM JN, Ng OT, Toh MPHS, Gao Q, et al.
   Predictors of disease severity in SARS-CoV-2 omicron variant XBB sublineages and
   variants of interest.
   J Med Virol. 2023;95:e29204.
   PubMed: https://www.amedeo.com/p2.php?id=37937705&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37937705
9. COLSON P, Bader W, Fantini J, Dudouet P, et al.
   From viral democratic genomes to viral wild bunch of quasispecies.
   J Med Virol. 2023;95:e29209.
   PubMed: https://www.amedeo.com/p2.php?id=37937701&s=cov&pm=2
   ABSTRACT available
   Share: https://m.amedeo.com/37937701
10. WANG Y, Wu L, Yu X, Wang G, et al.
    Development of a rapid, sensitive detection method for SARS-CoV-2 and influenza
    virus based on recombinase polymerase amplification combined with CRISPR-Cas12a
    assay.
    J Med Virol. 2023;95:e29215.
    PubMed: https://www.amedeo.com/p2.php?id=37933907&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37933907
11. BERGNA A, Lai A, Ventura CD, Bruzzone B, et al.
    Genomic epidemiology of the main SARS-CoV-2 variants in Italy between summer 2020
    and winter 2021.
    J Med Virol. 2023;95:e29193.
    PubMed: https://www.amedeo.com/p2.php?id=37927140&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37927140
12. RAZAI MS, Mansour R, Goldsmith L, Freeman S, et al.
    Interventions to increase vaccination against COVID-19, influenza and pertussis
    during pregnancy: a systematic review and meta-analysis.
    J Travel Med. 2023 Nov 2:taad138. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=37934788&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37934788
13. ALRUWAILI M, Armstrong S, Prince T, Erdmann M, et al.
    SARS-CoV-2 NSP12 associates with TRiC and the P323L substitution acts as a host
    adaption.
    J Virol. 2023 Nov 6:e0042423. doi: 10.1128/jvi.00424.
    PubMed: https://www.amedeo.com/p2.php?id=37929963&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37929963
14. HARRIS E.
    Convalescent Plasma Lowered Risk of Death in COVID-19 ARDS.
    JAMA. 2023 Nov 8. doi: 10.1001/jama.2023.21872.
    PubMed: https://www.amedeo.com/p2.php?id=37938859&s=cov&pm=2
     
    Share: https://m.amedeo.com/37938859
15. WANG Q, Bowen A, Ho J, Zhang RM, et al.
    SARS-CoV-2 neutralising antibodies after a second BA.5 bivalent booster.
    Lancet. 2023 Oct 31:S0140-6736(23)02278-X. doi: 10.1016/S0140-6736(23)02278.
    PubMed: https://www.amedeo.com/p2.php?id=37922920&s=cov&pm=2
     
    Share: https://m.amedeo.com/37922920
16. POESPOPRODJO JR, Douglas NM, Ansong D, Kho S, et al.
    Malaria.
    Lancet. 2023 Nov 1:S0140-6736(23)01249-7. doi: 10.1016/S0140-6736(23)01249.
    PubMed: https://www.amedeo.com/p2.php?id=37924827&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37924827
17. HOPKINS DR, Weiss AJ, Yerian S, Sapp SGH, et al.
    Progress Toward Eradication of Dracunculiasis – Worldwide, January 2022-June
    2023.
    MMWR Morb Mortal Wkly Rep. 2023;72:1230-1236.
    PubMed: https://www.amedeo.com/p2.php?id=37943706&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37943706
18. SEITHER R, Yusuf OB, Dramann D, Calhoun K, et al.
    Coverage with Selected Vaccines and Exemption from School Vaccine Requirements
    Among Children in Kindergarten – United States, 2022-23 School Year.
    MMWR Morb Mortal Wkly Rep. 2023;72:1217-1224.
    PubMed: https://www.amedeo.com/p2.php?id=37943705&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37943705
19. BELL J, Meng L, Barbre K, Haanschoten E, et al.
    Influenza and Up-to-Date COVID-19 Vaccination Coverage Among Health Care
    Personnel – National Healthcare Safety Network, United States, 2022-23 Influenza
    Season.
    MMWR Morb Mortal Wkly Rep. 2023;72:1237-1243.
    PubMed: https://www.amedeo.com/p2.php?id=37943704&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37943704
20. LYMON H, Meng L, Reses HE, Barbre K, et al.
    Declines in Influenza Vaccination Coverage Among Health Care Personnel in Acute
    Care Hospitals During the COVID-19 Pandemic – United States, 2017-2023.
    MMWR Morb Mortal Wkly Rep. 2023;72:1244-1247.
    PubMed: https://www.amedeo.com/p2.php?id=37943698&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37943698
21. LE VOYER T, Parent AV, Liu X, Cederholm A, et al.
    Autoantibodies against type I IFNs in humans with alternative NF-kappaB pathway
    deficiency.
    Nature. 2023 Nov 8. doi: 10.1038/s41586-023-06717.
    PubMed: https://www.amedeo.com/p2.php?id=37938781&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37938781
22. BOBY ML, Fearon D, Ferla M, Filep M, et al.
    Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors.
    Science. 2023;382:eabo7201.
    PubMed: https://www.amedeo.com/p2.php?id=37943932&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37943932
23. SHOICHET BK, Craik CS.
    Preparing for the next pandemic.
    Science. 2023;382:649-650.
    PubMed: https://www.amedeo.com/p2.php?id=37943911&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37943911
24. MUNOZ-DEL-CARPIO-TOIA A, Bartolo-Marchena M, Benites-Zapata VA, Herrera-Anazco P, et al.
    Mortality from COVID-19 in Amazonian and Andean original indigenous populations
    of Peru.
    Travel Med Infect Dis. 2023 Nov 7:102658. doi: 10.1016/j.tmaid.2023.102658.
    PubMed: https://www.amedeo.com/p2.php?id=37944653&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37944653
25. SAAG MS.
    Coronavirus Disease (COVID) and the Fog of War.
    Clin Infect Dis. 2023 Nov 8:ciad649. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=37946560&s=cov&pm=2
     
    Share: https://m.amedeo.com/37946560
26. KUPPALLI K.
    Hostility Unmasked: Scientists on the Frontlines of the Coronavirus Disease 2019
    (COVID-19) Pandemic.
    Clin Infect Dis. 2023 Nov 6:ciad623. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=37939781&s=cov&pm=2
     
    Share: https://m.amedeo.com/37939781
27. HUMPHRIES R, Sefers S, Schmitz J, Seegmiller A, et al.
    Clinical Laboratory Experiences During the Coronavirus Disease 2019 Pandemic.
    Clin Infect Dis. 2023 Nov 2:ciad622. doi: 10.1093.
    PubMed: https://www.amedeo.com/p2.php?id=37933663&s=cov&pm=2
     
    Share: https://m.amedeo.com/37933663
28. ASLAM S.
    Phage Therapy in Lung Transplantation: Current Status and Future Possibilities.
    Clin Infect Dis. 2023;77.
    PubMed: https://www.amedeo.com/p2.php?id=37932113&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37932113
29. SU WC, Chen ZY, Chang YS, Jeng KS, et al.
    Functional assessments of SARS-CoV-2 single-round infectious particles with
    variant-specific spike proteins on infectivity, drug sensitivity, and antibody
    neutralization.
    Antiviral Res. 2023 Nov 7:105744. doi: 10.1016/j.antiviral.2023.105744.
    PubMed: https://www.amedeo.com/p2.php?id=37944823&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37944823
30. KIM DG, Kim U, Park IH, Ryu B, et al.
    A bivalent form of a RBD-specific synthetic antibody effectively neutralizes
    SARS-CoV-2 variants.
    Antiviral Res. 2023 Nov 7:105738. doi: 10.1016/j.antiviral.2023.105738.
    PubMed: https://www.amedeo.com/p2.php?id=37944822&s=cov&pm=2
    ABSTRACT available
    Share: https://m.amedeo.com/37944822

https://etidioh.wordpress.com/2023/11/11/coronavirus-disease-research-references-by-amedeo-november-11-23/

#coronavirus #COVID19 #research #sarbecovirus #sarsCov2

Contrasting roles of #MERS-CoV and #SARS-CoV-2 internal #proteins in #pathogenesis in mice, mBio: https://doi.org/10.1128/mbio.02476-23 #research #betacoronavirus #sarbecovirus #merbecovirus

Diversity and independent evolutionary #profiling of #rodent-borne #viruses in #Hainan, a tropical island of #China, Virol Sin.: https://doi.org/10.1016/j.virs.2023.08.003 #EIDs #zoonoses #coronavirus #sarbecovirus #research

Impaired neutralizing #antibody #efficacy of #tixagevimab-cilgavimab 150+150 mg as pre-exposure #prophylaxis against #Omicron #BA5. A real-world experience in booster vaccinated immunocompromised patients, J Clin Virol.: https://doi.org/10.1016/j.jcv.2023.105584 #reseach #science #medicine #mAbs #betacoronavirus #sarbecovirus #covid19

A pan- #sarbecovirus #vaccine based on #RBD of #SARS-CoV-2 original strain elicits potent neutralizing #antibodies against #XBB in non-human primates https://www.pnas.org/doi/abs/10.1073/pnas.2221713120?af=R